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Dissection of the Neural Effects of Deep Brain Stimulation 
Jonathan Schor 
Abstract 
Deep brain stimulation (DBS) is a clinical and investigational treatment for a variety 
of neuropsychiatric conditions, such as Parkinson’s Disease (PD) and obsessive-
compulsive disorder. Despite widespread clinical use, its therapeutic mechanism is 
unknown. Previous results indicate DBS may produce a complex array of effects, ranging 
from inhibition in the STN to antidromic stimulation of cortical afferents, but it has proven 
difficult to establish how these changes interact to alter behavior. Here, we developed a 
mouse model of subthalamic nucleus (STN) DBS for PD to investigate this question using 
the mechanistic and cell type-specific tools available in mice.  
First, in Chapter 1 (Introduction) I detail various theories surrounding the 
mechanism of STN DBS and discuss the technical limitations that have prevented a 
definitive exploration from taking place.  
In Chapter 2 (Multiple stimulation parameters influence efficacy of deep brain 
stimulation in parkinsonian mice), I describe the development of a mouse model of 
electrical STN DBS for PD, and demonstrate that it recapitulates many of the salient 
features of STN DBS in human PD patients. I also describe a composite metric which can 
be used to characterize the relationship of DBS parameters to their behavioral efficacy in 
mice, and show that this relationship holds when the metric was applied retrospectively 
to human data. 
 v 
In Chapter 3 (Levodopa and STN Deep Brain Stimulation Relieve Parkinsonian 
Motor Symptoms with Opposing Changes in Basal Ganglia Activity), I report our findings 
using optical tools in a mouse model of PD, recording calcium signals as a surrogate 
marker of neural activity. In concordance with previous electrophysiological studies, we 
find that in parkinsonian mice, dopamine replacement therapy with levodopa causes large 
decreases in neural activity at the level of basal ganglia output (the substantia nigra pars 
reticulata, or SNr). In contrast, therapeutic electrical STN DBS increases activity in both 
the STN and SNr. Furthermore, we find that both optogenetic inhibition of SNr neurons, 
which mimics the effects of levodopa, and optogenetic excitation of STN neurons, which 
mimics the effects of STN DBS, are therapeutic in mice. 
Finally, in Chapter 4 (Conclusions), we discuss the implications of these findings 
and the role of future studies in further elucidating the mechanism of STN DBS. 
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 2 
Introduction 
The basal ganglia are a group of interconnected subcortical nuclei critical for 
movement, action selection, and motor learning1. These nuclei have also been implicated 
in a variety of neurological disorders, including Huntington’s Disease, dystonia, and 
Parkinson’s Disease (PD)2. In PD, the progressive loss of midbrain dopamine neurons 
and their projections to the input nucleus of the basal ganglia, the striatum, is believed to 
result in altered signaling in striatal direct and indirect pathway medium spiny neurons 
(dMSNs and iMSNs, respectively)2–4 (Fig 1.1 left and middle). According to the standard, 
or rate model of basal ganglia function, decreased dopamine produces overactivity in the 
indirect pathway, leading to decreases in the amplitude and velocity of voluntary 
movement3. Many PD motor symptoms are thus hypothesized to arise from abnormalities 
in neural activity. 
There are no disease-modifying therapies available for PD, but there are two major 
classes of symptomatic treatment, both of which focus on the motor symptoms: (1) 
dopamine replacement therapy and (2) Deep Brain Stimulation (DBS). The dopamine 
precursor levodopa boosts dopamine levels in the brain, and is hypothesized to restore a 
balance in the activity of the direct and indirect pathways, leading to improved motor 
function. Levodopa indeed alleviates many PD motor symptoms5. With chronic treatment, 
however, patients often develop motor fluctuations, including unpredictable benefits with 
each dose of levodopa, and drug-induced dyskinesias. If such fluctuations cannot be 
adequately managed with changes in dosing, many patients seek basal ganglia DBS. 
Electrical stimulation devices are most commonly implanted in the STN, a downstream 
target of the indirect pathway6 (Fig 1.1, right), though the globus pallidus pars interna 
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(GPi) is another common target. Basal ganglia DBS alleviates many of the motor 
symptoms of PD, allowing patients to drastically reduce their reliance on dopaminergic 
agents, thereby improving motor fluctuations. Despite the use of STN DBS for several 
decades, its mechanism of action remains unknown. 
 STN electrical stimulation may cause changes in the activity of (1) local STN cell 
bodies and their axons, (2) inputs to the STN from a variety of other structures, or (3) 
axons of passage. Which of these potential changes mediate the therapeutic effects of 
DBS is unknown. Initially, it was postulated that STN DBS relieved parkinsonian 
symptoms by inhibiting STN neurons and the nuclei to which they project, a theory based 
on the observation that in parkinsonian non-human primates (NHPs), STN lesions 
resulted in marked motor improvements7. Indeed, in humans, subthalamotomy also 
relieves parkinsonism8. According to this model, reducing STN activity would lead to 
decreased basal ganglia output, facilitating movement2,3 (Fig 1.1, right). Supporting this 
idea, some in vitro electrophysiological evidence has suggested that high frequency 
stimulation (HFS) may drive STN neurons into depolarization block, preventing further 
action potential firing9. Some in vivo electrophysiological studies also suggest STN cell 
bodies may be inhibited during HFS DBS10,11. However, these latter results are 
challenging to interpret, due stimulation artifacts in electrical recordings. Typical STN DBS 
requires continuous electrical stimulation at 120-180 Hz, which obscures the 20-40 Hz 
firing rates of STN neurons during electrophysiological recordings; even attempts at 
removing these artifacts may unintentionally alter the underlying data. In humans, direct 
recordings of the output nuclei can rarely be made during STN DBS12, and likewise few 
such recordings exist in animal models (NHPs13 or rats14). In addition, the heterogeneity 
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of cell types in basal ganglia nuclei make it possible that changes in one population of 
neurons might be hidden by opposing changes in other populations15, a phenomenon that 
could be detected using cell type-specific genetic tools now available in mice. 
In an effort to better understand how DBS relieves parkinsonian symptoms, 
previous rodent studies have used optogenetics to mimic STN DBS with pulsed light16,17. 
These studies have led to a competing theory involving the hyperdirect pathway, which 
carries excitatory projections from the cortex to the STN18,19 (Fig 1.1, orange). According 
to this theory, electrical STN DBS causes antidromic activation of a population of cortical 
neurons that project to the STN. A systematic dissection of the afferent circuitry to the 
STN using optogenetics in mice revealed that high frequency activation of STN-projecting 
primary motor cortex (M1) neurons (hyperdirect pathway) was sufficient to recapitulate 
many of the therapeutic benefits seen in STN DBS patients16,17. While it is unclear how 
well optical stimulation mirrors electrical DBS as used in human patients, subsequent 
research showed that in a rat model, as well as in patients, electrical STN DBS indeed 
does evoke antidromic spikes in M1 afferents and disrupts cortical rhythmic oscillations 
seen during parkinsonism20–22. These results are consistent with, but do not prove, the 
idea that antidromic stimulation of cortical inputs underlies the therapeutic effects of 
electrical STN DBS. Unfortunately, while these studies generated several theories of how 
DBS works23, their technical limitations and distinct differences from DBS as used in PD 
patients (electrical artifacts, optical rather than electrical stimulation) prevent directly 
testing whether hyperdirect pathway mechanisms are required for the therapeutic effects 
of STN DBS. 
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Though initial theories about how DBS altered neural circuits and produced 
therapeutic effects in PD focused on changes in firing rate, accumulating data in human 
patients as well as animal models suggest that the pathophysiology of PD might more 
closely relate to changes in firing pattern at the individual or ensemble level. Multiple 
groups have found changes in the bursting of basal ganglia neurons12,13,24, as well as 
alterations in the local field potential (LFP) in PD and in animal models25. Since these 
discoveries, investigators have also found that beta oscillations correlate with disease 
symptoms26, and are reduced in response to treatment with either levodopa27 or STN 
DBS28. Over the past two decades, theories regarding therapeutic mechanisms of STN 
DBS have increasingly revolved around the idea that pathological oscillations are 
disrupted by therapeutic manipulations. 
Though STN DBS broadly impacts neural circuitry, it is unknown which changes 
are critical to its therapeutic benefit. Perhaps the most critical roadblock is the inability to 
perform electrical STN DBS while using cell type-specific techniques to monitor and 
manipulate neural activity in the STN and connected nuclei. Fortunately, when I began 
my inquiry a number of methods became available that allow for optical recordings in 
freely moving mice, with the caveat that no one had previously characterized the effect of 
STN DBS in a parkinsonian mouse model. Therefore, through a combination of electrode 
engineering and stereotactic targeting, we developed a mouse model of STN DBS in PD 
and used it to address some of the key questions in the field:  
(1) What is the parameter space for therapeutic STN DBS?  
(2) What is the effect of STN DBS on STN and SNr activity in vivo?  
(3) Which of the changes caused by STN DBS produce therapeutic benefit? 
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Figure 1.1 
 
 
 
 
 
 
 
 
 
Figure 1.1. Model of the basal ganglia in health and disease. A schematic depicting 
the classical rate model of the basal ganglia in both a healthy mouse and a parkinsonian 
mouse following dopamine depletion, as well as one of the proposed mechanisms for 
STN DBS (¯ = excitatory, ^ = inhibitory).  
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Chapter 2: 
Multiple stimulation parameters influence efficacy of 
deep brain stimulation in parkinsonian mice‡ 
 
 
 
 
 
 
 
 
 
‡A version of this chapter was published as Schor JS, Nelson AB. Multiple stimulation 
parameters influence efficacy of deep brain stimulation in parkinsonian mice. The 
Journal of Clinical Investigation. 2019 June 13;130:3833-3838. 
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Multiple stimulation parameters influence efficacy of deep 
brain stimulation in parkinsonian mice 
Abstract 
 Deep brain stimulation (DBS) is used to treat multiple neuropsychiatric disorders, 
including Parkinson’s Disease (PD). Despite widespread clinical use, its therapeutic 
mechanisms are unknown. Here, we developed a mouse model of subthalamic nucleus 
(STN) DBS for PD, to permit investigation using cell type-specific tools available in mice. 
We found that electrical STN DBS relieved bradykinesia, as measured by movement 
velocity. In addition, our model recapitulated several hallmarks of human STN DBS, 
including rapid onset and offset, frequency dependence, dyskinesia at higher stimulation 
intensity, and associations between electrode location, therapeutic benefit, and side 
effects. We used this model to assess whether high frequency stimulation is necessary 
for effective STN DBS, or if low frequency stimulation can be effective when paired with 
compensatory adjustments in other parameters. We found that low frequency stimulation, 
paired with greater pulse width and amplitude, relieved bradykinesia. Moreover, a 
composite metric incorporating pulse width, amplitude, and frequency predicted 
therapeutic efficacy better than frequency alone. We found a similar relationship between 
this composite metric and movement speed in a retrospective analysis of human data, 
suggesting correlations observed in the mouse model may extend to human patients. 
Together, these data establish a mouse model for elucidating mechanisms of DBS. 
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Introduction 
Parkinson's Disease (PD) is a neurodegenerative disease characterized by motor 
deficits, including bradykinesia (slowed movement), rigidity, and tremor. Dopamine 
replacement therapy relieves many motor symptoms, but is often complicated by the 
development of prominent motor fluctuations and involuntary movements1. With few 
effective pharmacological alternatives, patients are often implanted with electrodes in 
basal ganglia nuclei for chronic stimulation. Deep brain stimulation of the subthalamic 
nucleus (STN DBS)2 is highly effective in relieving bradykinesia, rigidity, and tremor3. 
Despite several decades of clinical experience, however, the underlying mechanisms and 
ideal therapeutic parameters for STN DBS remain unclear4 . 
The basal ganglia circuit in PD patients exhibits abnormal firing rate, pattern, and 
synchronization5; STN DBS may disrupt or correct one or a number of these changes. At 
present, clinical practice is delivery of continuous pulsatile stimulation at high frequency. 
Therapeutic benefit depends on the frequency, current amplitude, and pulse width of 
stimulation4. One theory postulates that high frequency stimulation (HFS, over 90Hz) 
disrupts abnormal basal ganglia activity6, while other parameters (pulse width and 
current) may allow spread of stimulation through the STN. In fact, HFS provides greater 
relief of bradykinesia and tremor, whereas very low frequency stimulation (LFS, around 
10Hz) can be ineffective or even potentially deleterious7. However, a less widely held 
hypothesis is that any manipulation that perturbs neuronal firing may disrupt abnormal 
activity, and thus clinicians can compensate for a low setting of any one parameter 
(frequency, pulse width, or current) by increasing the other two; one study found the 
current amplitude necessary to relieve rigidity varied inversely with the pulse width8. A 
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better understanding of how individual parameters contribute to STN DBS efficacy would 
not only improve symptom management in patients, but might also identify potential 
therapeutic mechanisms of STN DBS. 
Though electrical DBS has been demonstrated in both parkinsonian nonhuman 
primates9,10 and rats11,12, a mouse model, combined with the extensive mouse genetic 
toolbox, would permit complementary cellular and circuit investigations of DBS 
therapeutic mechanisms. Here, we developed a mouse model of STN DBS in 
hemiparkinsonian mice. Stimulation relieves bradykinesia and recapitulates a number of 
features of STN DBS in human patients. We use this model to investigate the relationship 
between stimulation parameters and therapeutic efficacy, as well as adverse effects, and 
find that a composite metric based on all three stimulation parameters predicts STN DBS 
efficacy. This relationship also holds in a retrospective analysis of human data, 
suggesting shared therapeutic features in human and mouse STN DBS. Together, our 
results provide a valuable tool for predicting DBS efficacy, as well as a model for further 
investigation of STN DBS. 
Results 
Parkinsonian mouse models have contributed to our understanding of both 
disease pathophysiology and the actions of levodopa5. However, it is not known whether 
parkinsonian mice respond to electrical STN DBS in similar ways to patients. We 
identified six clinical features of STN DBS for PD, which we used as criteria in a mouse 
model of STN DBS: (1) STN DBS reduces bradykinesia, (2) motor benefits are time-
locked to stimulation, (3) relief of bradykinesia is frequency dependent13; (4) increasing 
stimulation intensity (across multiple parameters) results in dyskinesia14; (5) dorsal STN 
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stimulation is more effective than ventral stimulation in relieving bradykinesia15; (6) and 
stimulation closer to the pyramidal tract is more likely to evoke motor contractions16. 
With these criteria in mind, we designed and implanted unilateral 6-lead electrodes 
(divided into 3 bipolar pairs) in the STN of adult hemiparkinsonian mice, using the 
unilateral 6-hydroxydopamine (6-OHDA) model (Figure 2.1A-C). In these mice, 
parkinsonism was manifest as both ipsilesional rotational bias (Supplemental Figure 
2.1G, see pre vs healthy) and decreased movement velocity (Figure 2.1H, see pre vs 
healthy). We used the latter indicator as a measure of bradykinesia, though it may also 
incorporate other parkinsonian features such as gait dysfunction. We constructed our 6-
lead electrodes to span ~300-600µm (covering the ~250µm vertical span of mouse STN) 
and implanted them in the ipsilesional STN (Figure 2.1D-E, Supplemental Figure 2.1A-
B). We selected the optimal electrode pair by stimulating at settings mirroring typical 
human DBS and DBS in rat models12,17 (120Hz, 200µA, 60µs with bipolar, biphasic 
square waves, Supplemental Figure 2.1C). The stimulated pair eliciting the highest 
average movement velocity was used for subsequent experiments (Supplemental Figure 
2.1D). Stimulation at these DBS parameters increased movement velocity in mice (Figure 
2.1F-G, Supplemental Video 1); velocity changed at short latency from onset (3.19 +/- 
0.65 sec) and offset (0.66 +/- 0.10 sec) of stimulation, corroborating clinical features (1) 
and (2). We used 1-minute stimulation epochs to efficiently evaluate a wide array of 
stimulation parameter combinations but found that longer periods of stimulation (10 
minutes) produced similar improvements in movement velocity (Supplemental Figure 
2.1E). These findings suggest that STN DBS in parkinsonian mice and PD patients share 
core therapeutic features.  
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We next explored whether STN DBS in hemiparkinsonian mice shows frequency 
dependence, as has been observed in humans (criterion 3)7,13. To address this question, 
we varied stimulation frequency while holding current amplitude and pulse width constant 
(200µA and 60µs). Movement velocity scaled relatively linearly with frequency up to 
approximately 120Hz (Figure 2.1H), mirroring observations in patients using hand tapping 
speed as the outcome measure13. However, the range of effective frequencies was much 
wider (as low as 15Hz) than reported in patients. In addition to absolute velocity, STN 
DBS also improved other well-established metrics17 such as percent-time moving and 
relative velocity (normalized to pre-stim period) in a frequency-dependent manner, though 
rotational bias was not significantly changed (Supplemental Figure 2.1F-H). In humans, 
dyskinesia emerges as a side effect of higher frequency stimulation14. Likewise, we found 
that in mice, higher frequency stimulation, as well as increased pulse width and current, 
evoked dyskinesia18 (Figure 2.2A). These findings suggest that in parkinsonian mice, as 
in humans, both therapeutic and dyskinetic effects of stimulation relate to stimulation 
frequency. 
To assess the relationship of stimulation location to therapeutic efficacy and 
dyskinesia (criteria 5 and 6), we determined the location of DBS in postmortem tissue. 
Following terminal anesthesia, we made electrolytic lesions using the therapeutic leads 
(Figures 2.1E, 2.2B). We correlated dorso-ventral location with the relative velocity of 
each mouse at standard stimulation settings (120Hz, 200µA, and 60µs). As in humans, 
greater improvements in velocity were seen with more dorsal STN stimulation (Figure 
2.2C). This may relate to targeting sensorimotor STN territories19,20 or the zona incerta, 
stimulation of which is also therapeutic21,22. We next correlated electrode distance from 
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the pyramidal tract with the dyskinesia score in response to stimulation at 120Hz, 300µA, 
and 120µs (parameters which reliably evoked dyskinesias in over half of mice). Again, 
the mouse model mirrored human data: mice with electrodes closer to the pyramidal tract 
had greater dyskinesia (Figure 2.2D). Our model fulfilled all six clinical criteria, 
recapitulating key features of human DBS and indicating it may be a useful tool in 
understanding STN DBS mechanisms. 
A dominant theory is that high- and low-frequency stimulation (HFS and LFS, 
respectively) produce qualitatively different changes in basal ganglia activity, and thus 
only HFS is efficacious7. Alternatively, any combination of frequency, current, and pulse 
width that sufficiently disrupts STN-basal ganglia circuit activity may be therapeutic. To 
test these theories using our model, we first assessed the relationship of each of the three 
variables (current, frequency, and pulse width) to movement velocity, while holding the 
other two constant. As we previously observed, movement velocity showed a strong linear 
correlation with frequency, when pulse width and current were held at constant (Figure 
2.3A). However, we also observed strong linear relationships when only varying pulse 
width (Figure 2.3B) or current (Figure 2.3C), suggesting each variable individually 
contains linear predictive value. These individual parameters can also be combined in a 
metric cited in the clinical DBS literature: Total Electrical Energy Delivered (TEED)23. 
TEED is calculated as [current2 * frequency * pulse width] / impedance. We found that 
current-squared, one term in this metric, was also linearly correlated with movement 
velocity (Figure 2.3D). Together, these results support the idea that many parameter 
combinations can provide therapeutic benefit.  
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While within the limited range tested, all three parameters correlated with 
therapeutic benefit, we wondered whether a combined metric might predict benefit across 
a wider set of parameters. If so, such a metric might prove a useful tool for clinicians. To 
explore this possibility, we stimulated using 31 different parameter combinations 
(Supplemental Figure 2.2A, Supplemental Table 2.1) and measured the resulting 
movement velocity. We collapsed each parameter combination into a single value (picombo, 
where the “i” subscript indicates constant-current stimulation), calculated as current2 * 
frequency * pulse width.  picombo is based on TEED, but we ascribe no physical meaning 
to this composite metric and use it only to compare different parameter combinations. We 
found that the effectiveness of DBS, as measured by movement velocity, scaled linearly 
with picombo (Figure 2.3E). This relationship held across stimulation bouts when parameter 
combinations were grouped into three picombo levels (Supplemental Figure 2.2B). These 
results also indicate many different parameter combinations may be effective.  
In PD patients, optimal stimulation parameters often change over the first few 
months of DBS use; typically one or more parameters must be increased to maintain 
efficacy24, possibly related to alterations in both the electrodes and the surrounding 
tissue25. To test for this phenomenon in mice, we performed STN DBS in the same 9 mice 
at 50 new parameter combinations approximately two months later (Supplemental Figure 
2.2A, Supplemental Table 2.2). Consistent with human data, mice showed less benefit 
from stimulation at later time points (Supplemental Figure 2.2C, comparing slopes of solid 
and dotted lines), but DBS efficacy again scaled linearly with picombo (Supplemental Figure 
2.2C). With these parameters we also manually scored dyskinesia and found severity 
scaled linearly with picombo (Supplemental Figure 2.2D). These findings are consistent with 
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the idea that a composite metric incorporating stimulation pulse width, amplitude, and 
frequency consistently explains much of the variance in both the therapeutic and 
dyskinetic effects of STN DBS. 
We next generated a model for DBS efficacy, using the regression between 
stimulation parameters and movement velocity in early DBS testing. This model was 
based on picombo (Supplemental Figure 2.3A-D) and predicts that when current and pulse 
width are held at levels mimicking standard human stimulation, DBS efficacy will show 
frequency dependence (Supplemental Figure 2.3B-C). However, a more comprehensive 
exploration of parameter space revealed that increased pulse width and current amplitude 
can be used to compensate for reduced frequency, extending the range of effective DBS 
parameters. Similar results were observed when a model was created based on the 
regression from late DBS testing (Supplemental Figure 2.3E-H), though due to the 
shallower slope of the late DBS regression, the same combination of any three 
parameters produced less therapeutic benefit than in the early model. These models not 
only explain previous clinical observations but may provide valuable individualized 
visualizations of effective parameters for future PD patients. 
 To determine whether the picombo metric could be used with individual stimulation 
site data to predict relationships between stimulation site and therapeutic efficacy and/or 
dyskinesia, we calculated a new metric for therapeutic efficacy. We calculated the slope 
of the correlation between picombo and movement velocity (vel slope; Supplemental Figure 
2.4A), representing the additional benefit derived from unit increases in picombo. We found 
that electrode location along the dorso-ventral axis showed a modest correlation with vel 
slope (Supplemental Figure 2.4B), consistent with human observations and our data at a 
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single stimulation setting (Figure 2.2C). We next calculated a similar metric for dyskinesia: 
the slope of the correlation between picombo and the dyskinesia score (dysk slope), an 
indicator of tendency toward stimulation-induced dyskinesia. In line with our data from a 
single stimulation setting (Figure 2.2D), we observed that electrodes closer to the internal 
capsule tended to have higher dysk slopes (Supplemental Figure 2.4C). Finally, and 
perhaps most excitingly, we found no correlation between vel slope and dysk slope 
(Supplemental Figure 2.4D). These findings suggest that despite a shared correlation 
with picombo, improved DBS efficacy and the vulnerability to dyskinesias may be 
dissociable. 
 Optimizing patient DBS parameters is common, but extensive controlled testing is 
challenging in a clinical setting. Indeed, few studies have explored parameter space while 
measuring quantitative outcomes. However, one human study tested a subset of the 
parameter space (voltage, frequency, and pulse width) described here, using hand 
tapping as a measure of bradykinesia13. We reanalyzed this data to determine if a similar 
relationship between stimulation parameters and therapeutic effects governs STN DBS 
in PD patients. Based on parameter combinations tested in all 12 patients within a range 
equivalent to those tested in mice (Supplemental Figure 2.2B, Supplemental Table 2.3), 
we calculated a constant-voltage version of picombo (pvcombo=voltage2 * frequency * pulse 
width) and estimated efficacy. We found that tapping speed was strongly correlated with 
pvcombo (Figure 2.3F). These human results are consistent with our findings in 
parkinsonian mice: STN DBS efficacy for bradykinesia (as measured by locomotor 
velocity) scales linearly with a combined metric incorporating all three stimulation 
parameters. 
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Discussion 
Though STN DBS has provided symptomatic relief to PD patients for over two 
decades, ideal parameters for DBS, as well as their underlying therapeutic mechanisms, 
are still unclear. We used a set of custom-built tools to create a model of STN DBS in 
hemiparkinsonian mice, and leveraged this model to rigorously explore the parameter 
space for effective DBS. We found that STN DBS is not only effective in restoring near-
normal levels of locomotion in parkinsonian mice, but that it recapitulates many key 
features of STN DBS in PD patients. We found low frequency DBS could be effective, 
provided pulse width and current amplitude were adjusted to compensate. Indeed, 
behavioral effectiveness depended linearly on a combination of all three parameters, 
picombo, suggesting a much larger and more predictable parameter space than previously 
assumed. Finally, we found that a similar metric strongly predicted relief of bradykinesia 
in a human DBS dataset; however, due to differences in brain size, parkinsonism 
features, and the stimulation devices used between humans and mice, further human 
studies are clearly needed. 
Our findings support the hypothesis that stimulation frequency does not uniquely 
predict DBS efficacy; indeed, multiple recent human studies also report low frequency 
DBS is effective26,27. This relationship may not have been detected previously due to 
practical clinical barriers to systematic study of parameter space as well as outcome 
measures used. Utilizing a model such as ours facilitates a wider and more standardized 
exploration of parameter space, which can be used to generate new hypotheses for 
optimal human treatment. 
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We hope the STN DBS mouse model presented here can serve as a new platform, 
allowing the use of the powerful mouse genetic toolbox to investigate how STN DBS 
modifies activity patterns in basal ganglia-thalamocortical circuits. These tools, such as 
genetically-encoded calcium and voltage sensors, as well as optical and chemical 
manipulators of neural activity, will allow causal investigation of DBS therapeutic 
mechanisms in the future, complementing ongoing groundbreaking work in patients, non-
human primates, and rat models.  
Methods 
Study approval 
 All the animal studies were approved by the Institutional Animal Care and Use 
Committee of the University of California San Francisco. 
Experimental design 
The aim of this study was to develop a model of STN DBS in hemiparkinsonian mice, and 
to evaluate the parameter space for effective STN DBS in this model. Our hypothesis, 
based on pilot studies, was that the parameter space would mirror the space described 
for human PD patients and depend largely upon the frequency of stimulation rather than 
pulse width or current amplitude. Experiments were designed based on power analyses 
that indicated a minimum of 10 mice would be necessary to detect behavioral differences 
between effective and ineffective stimulation parameters. Stimulation parameter order 
was randomized across all mice and predefined quantitative measures of motor 
performance were used to assess changes in parkinsonian symptoms. Though we tested 
11 parkinsonian mice in this study, postmortem tissue for anatomical confirmation of the 
stimulation site could not be recovered from two mice, and thus their behavioral data was 
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excluded from the study. To verify that 1- and 10-minute stimulation epochs evoked 
similar increases in movement, an additional cohort of 7 mice were evaluated. A third 
cohort of 5 mice was used in Figure 2.3B-D to determine how velocity scales with pulse 
width or current while all other parameters are held constant. 
Surgical procedures 
All surgical procedures were performed stereotactically on 3-6 month old C57BL/6 mice 
(Jackson Laboratory). Anesthesia was induced with intraperitoneal (IP) injection of 
ketamine/xylazine (0.1mL, 1mg/mL) and maintained with 0.5-1% inhaled isofluorane. The 
neurotoxin 6-hydroxydopamine (6-OHDA, 1µL, 5mg/mL in normal saline) was injected 
unilaterally in the medial forebrain bundle (MFB, -1.0 AP, -1.0 ML, 4.9 DV). Desipramine 
(0.2mL, 2.5mg/mL) was injected intraperitoneally (IP) just prior to surgery to reduce 
uptake by serotonergic and noradrenergic neurons in the MFB. This procedure resulted 
in near-complete loss of ipsilateral dopaminergic innervation of the striatum and severe 
hemiparkinsonism. After surgery, animals received analgesic agents and IP saline. 
During the first week of recovery, cages were placed on a heating pad and animals 
received supplementary IP saline, gel nutritional supplements, and softened food. A 
minimum of two weeks following dopamine depletion, mice were implanted with a 6-lead 
bipolar stimulating electrode array in the ipsilesional STN (-1.4 AP, -1.65 ML, 4.5 DV). 
Mice recovered for at least 1 additional week before stimulation testing began. 
Electrode fabrication 
Six-lead bipolar stimulating electrodes were constructed by twisting together and heating 
6 stainless steel 76.2µm coated wires (A-M Systems). The six untwisted ends were then 
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stripped using a razor blade and pressure fit into female Millmax connectors. Each 
electrode was tested for short circuits prior to implantation. 
Electrical stimulation 
An isolated constant current bipolar stimulator (WPI) was used to deliver electrical stimuli. 
The stimulator had a maximum voltage supply of >100 volts, a rise time of 6µs, and a 
built-in alarm indicating when the voltage limit was exceeded. We calculated that even at 
the highest settings used here we would not reach more than 80% of the total voltage 
available (ensuring accurate current delivery), a conclusion supported by the fact that the 
built-in voltage limit alarm did not sound during any of the experiments. The timing of 
stimuli was controlled by TTL input from an Arduino. Maximum current amplitude was set 
at 400µA, based on pilot experiments in which seizures occurred in some mice at or above 
this level.  
Optimal stimulation electrode determination 
Optimal stimulation electrode pairs were determined following STN DBS implantation 
based on the behavioral response of each pair in the open field setting. Each of the 3 
electrode pairs were stimulated at standard settings (200µA, 60µs pulse-width, 120Hz) 
for 1 minute, flanked by 1 minute stim-off rest periods. The electrode pair eliciting the 
largest increase in velocity during stimulation epochs was used for all subsequent studies 
(Supplemental Figure 2.1D). In one mouse, a short developed between its optimal 
electrode pair in the interval between early and late stimulation phases, so the electrode 
pair was switched during the late phase to another pair that had shown similar efficacy to 
the optimal pair during initial characterization. 
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Open field behavior 
Following optimal electrode pair selection, efficacy of STN DBS in parkinsonian mice was 
assessed in the open field (a transparent acrylic cylinder with a diameter of 25cm) during 
11-minute trials in which 1-minute epochs of stimulation were alternated with 1-minute 
epochs of no stimulation (rest). Every trial began and ended with a rest epoch, resulting 
in a total of 5 stimulation epochs and 6 rest epochs per trial. The parameters of stimulation 
were consistent within each trial and varied randomly between trials. Possible parameter 
combinations were chosen from a list of 81 parameters, half of which were 
pseudorandomly generated (current drawn from 0 to 300µA, frequency drawn from 0 to 
200Hz, pulse width drawn from 0 to 120µs, all in integer increments) while the other half 
were deliberately selected. All mice received at least 1 trial with each parameter. A 
composite metric, picombo, was calculated for each parameter combination using the 
formula picombo= [current2 * frequency * pulse width]23. 
Dyskinesia during stimulation and rest epochs was quantified using a modified 
version of the abnormal involuntary movements (AIM) scoring method18 . Dyskinesia was 
monitored online by one unblinded rater, and a subset of videos (222 minutes) were re-
scored offline by one blinded rater to ensure low inter-rater variability (average difference 
between raters’ individual AIM scores = 0.05 +/- 0.009). Dyskinesia was quantified in one-
minute increments during each trial, with axial, limb, and orofacial body segments rated 
on a scale of 0-3 each. A score of 0 indicates no abnormal movement, while a score of 3 
indicates abnormal movements during the entire minute-long epoch. The scores are then 
summed, for a maximum score of 9 per epoch. 
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Following each trial, video-tracking software (Noldus Ethovision) was used to 
calculate the velocity, percent time moving, and rotational bias of each mouse (calculated 
as rotational bias = ipsilateral rotations / (ipsilateral rotations + contralateral rotations), 
and all metrics were compared between stimulation and rest epochs. As the dyskinesias 
observed in our study largely did not provoke changes in the center of mass of the mouse 
they did not contaminate the calculation of velocity and thus no additional processing was 
required to separate the two. 
The onset of stimulation-induced changes in velocity was defined as the first time 
point during a stimulation bout in which the velocity was three standard deviations above 
the mean of the pre-stim period. The offset of stimulation-induced changes in velocity was 
defined as the first time point during each post-stimulation period in which velocity 
returned to the mean of the respective pre-stim period. 
All mice initially experienced 31 of the 81 parameters within a 1 to 3-week period, 
approximately 1 month following implantation (early DBS). They then experienced the 
remaining 50 parameters during a 3-week period, approximately 3 months following 
implantation (late DBS), in order to assess changes in DBS efficacy. 
For 10-minute stimulation epochs performed in a separate cohort of 7 mice 
(Supplemental Figure 2.1E), trials lasted for 30 minutes and consisted of a 10-minute pre-
stim period, followed by a 10-minute stim period, and concluded with a 10-minute post-
stim period. To account for habituation-related declines in spontaneous movement for 
these longer sessions, velocity during 120Hz stimulation was normalized to the average 
velocity during a 30-minute no-stimulation trial. Standard error for this normalized velocity 
was calculated through propagation of error. 
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Locomotion in healthy mice  
Open field locomotor data for healthy, nonparkinsonian controls was obtained from a 
separate cohort of mice with intracranial implants and headstage cables, so as to closely 
replicate the potential effects of tethering in STN DBS mice. Tracking data (Noldus) was 
analyzed in the same fashion as in parkinsonian mice: nonparkinsonian controls were 
only analyzed for movement metrics within the first 10 minutes of recording. 
Human data 
All human data were estimated from bar graphs provided by Moro, et al13. In order to 
analyze human data in as similar a fashion as possible to the mouse data collected here, 
only parameter combinations in which all 12 patients had participated were used. 
Additionally, only parameters that fell within a range equivalent to those tested in mice 
were used (frequency between 0 and 200Hz and pulse width between 0 and 120µs). For 
determining voltage range (since our mice were tested using constant current), we used 
a range from 0V to twice as high as the patient average for current clinical settings (since 
our maximum tested current, 400µA, was twice our estimate for standard human 
parameters, 200µA, and since current and voltage scale linearly). Thus, voltages between 
0 and 6.2V were considered. To adjust picombo for constant voltage rather than constant 
current, we used the formula pvcombo= [voltage2 * frequency * pulse width]. 
DBS model 
The models for DBS efficacy were developed using the regressions generated in Figure 
2.3E (for Supplemental Figure 2.3A-D) and Supplemental Figure 2.2C (for Supplemental 
Figure 2.3E-H) to calculate predicted velocity for parameters within the space shown 
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(current from 0-400µA in 20µA increments, frequency from 0-200Hz in 10Hz increments, 
and pulse width from 0-200µs in 10µs increments). 
Statistics  
All behavioral data recorded with video tracking (Noldus Ethovision) was exported to 
Matlab (Mathworks) for offline analysis. Statistical differences between stimulation 
parameters were assessed using one-way repeated-measures ANOVA, followed by post 
hoc comparisons using Tukey’s Honest Significant Difference procedure. Padjusted 
reported for ANOVAs is a p-value with the most conservative lower bound adjustment, as 
calculated by Matlab. Linear correlations and adjusted R-squared values were calculated 
in Matlab by fitting data to a linear model. The generalized linear model was created in 
Matlab using a normal distribution. 
Histology 
Accurate targeting of STN DBS electrodes and successful depletion of dopaminergic 
projections to the striatum were confirmed histologically following perfusion. Two mice, 
out of the original cohort of 11, were excluded from analysis as postmortem tissue 
(confirming electrode localization) could not be recovered. Mice were deeply anesthetized 
with IP ketamine/xylazine (1 ml, 1mg/mL). In order to aid in locating STN DBS electrode 
tips in postmortem tissue, we electrolytically lesioned the two leads used for behavioral 
experiments with 150µA of monopolar direct current for 5 seconds, just prior to 
transcardial perfusion with paraformaldehyde (PFA). The brain was dissected from the 
skull, post-fixed overnight in 4% PFA, then stored in 30% sucrose at 4°C. Brains were 
then sliced in 30 µm sections on a freezing microtome (Leica) and dopamine depletion 
was verified via tyrosine hydroxylase (TH) immunohistochemistry. Briefly, sections were 
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washed in PBS (5x10 minutes) and blocked in normal donkey serum (NDS)/0.1% Triton-
X (1hr at room temperature, RT), followed by incubation in primary antibody (Pel-Freez 
rabbit anti-TH, 1:1000 at 4°C overnight) and secondary antibody (donkey anti-rabbit 647 
nm, Jackson Immunoresearch, 1:500 in NDS at RT for 2hrs). Following mounting on glass 
slides (Vectashield Mounting Medium), sections were imaged in the Cy5 (excitation 
650nm, emission 684nm) channel and stitched fluorescence images were taken on a 
Nikon 6D conventional wide-field microscope at 4-10X, using custom software (UCSF 
Nikon Imaging Center). Coordinates of mouse DBS electrodes were determined from 
histological images using a standard mouse brain atlas (Paxinos and Franklin). Center 
coordinates for the dorsal border pyramidal tract were determined in a similar way, and 
distance between this point and the coordinates of the electrode for each mouse was 
calculated using Euclidean distance. 
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Figure 2.1 
 
 
Figure 2.1. Subthalamic nucleus deep brain stimulation (STN DBS) alleviates 
bradykinesia in parkinsonian mice across a wide range of frequencies.  
(A) Experimental timeline. (B) Sagittal schematic showing unilateral 6-OHDA medial 
forebrain bundle (MFB) injection. (C) Representative coronal section immunostained for 
tyrosine hydroxylase (TH) showing ipsilateral depletion of striatal TH (scale bar = 
750µm). (D-E) Coronal schematic (D) and histological section (E); scale bars = 250 and 
750µm) showing ipsilesional STN targeting of DBS electrode (dotted white line and 
terminal electrolytic lesion). (F) Representative open field movement before, during, and 
after 120Hz STN DBS in a parkinsonian mouse (5 minutes each). (G) Representative 
raw velocity traces over standard 11-minute trials, consisting of five 1-minute bouts of 
5Hz, 20Hz, 120Hz, and 160Hz STN DBS interleaved with six 1-minute rest bouts. (H) 
Average velocity of parkinsonian mice during stimulation epochs across frequencies 
with constant pulse width (60µs) and constant current (200µA). Healthy refers to 
nonparkinsonian mice. Pre and post refer to 30 seconds before and after stimulation. 
Box extends from 25th to 75th percentile, median is indicated by horizontal line. Whiskers 
represent max and min values. (N=9 healthy mice, N=9  parkinsonian mice; 
Significance determined by one-way repeated measures ANOVA followed by Tukey’s 
Honest Significant Difference test, * p<.05 compared to pre-stim period). 
IP=intraperitoneal, Ctx=cortex, Str=striatum, SNc=substantia nigra pars compacta, 
IC=internal capsule, STN=subthalamic nucleus.   
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Figure 2.2 
 
Figure 2.2. STN DBS in parkinsonian mice recapitulates key features of human 
DBS.  
(A) Average abnormal involuntary movement (AIM) score of parkinsonian mice during 
1-minute stimulation epochs as a function of current (Top), pulse width (Middle), or 
frequency (Bottom), holding the other two parameters constant (N=9, 5 trials per mouse 
per condition). (B) Stimulation sites across all mice, as determined postmortem (N=9; 
red dots). (C) Correlation between dorsoventral (DV) stimulation site and velocity 
increases for individual mice at standard parameters (N=9). (D) Correlation between the 
stimulation site-pyramidal tract distance and average AIM score for individual mice at 
the parameter setting shown (N=9). Significance determined by one-way repeated 
measures ANOVA (performed on all stimulation parameters shown in (A)) followed by 
Tukey’s Honest Significant Difference test, * p<.05 compared to lowest stimulation 
setting. N=mice. 
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Figure 2.3 
 
 
Figure 2.3. Effectiveness of STN DBS depends linearly on a composite 
stimulation parameter metric, pcombo. 
(A-D) In parkinsonian mice, correlation of velocity during DBS with (A) frequency (N=9), 
(B) pulse width (N=5), (C) current (N=5), or (D) current-squared (N=5), holding the other 
two parameters constant. (E) In parkinsonian mice, correlation of velocity with picombo 
following DBS (31 conditions, N=9). (F) In humans, correlation of % of baseline tapping 
speed with pvcombo (9 conditions, N=12) during DBS (reanalyzed from Moro, et al13). 
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N=mice or humans. Each point represents an average across subjects and trials for a 
given condition. 
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Supplemental Figure 2.1 
 
Supplemental Figure 2.1. STN DBS improves multiple movement metrics in 
hemiparkinsonian mice. 
A) Photograph of DBS electrodes implanted in parkinsonian mice (scale bar = 1mm). (B) 
Schematic of experimental behavioral setup, including custom motorized commutator. (C) 
Diagram of bipolar, biphasic stimulation delivered during experimentation. (D) Sample 
raw velocity trace for optimal electrode pair determination. (E) Normalized velocity during 
10 minute stimulation epochs (green bar). Dark line indicates averages, while lighter 
shading indicates +/- SEM (N=7). (F-H) Relative velocity (F), rotational bias (G), and 
percent time moving (H) of parkinsonian mice during stimulation (1min) at the denoted 
frequencies, with pulse width (60µs) and current (200µA) held constant. Pre and post 
refer to 30 seconds before and after stimulation. Box extends from 25th to 75th percentile, 
median is indicated by horizontal line. Whiskers represent max and min values. (N=9 for 
healthy, N=9 for parkinsonian). Significance determined by one-way repeated measures 
ANOVA followed by Tukey’s Honest Significant Difference test, * p<.05 compared to pre-
stim period. N=mice. 
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Supplemental Figure 2.2 
 
 
Supplemental Figure 2.2. Both dyskinesia and DBS efficacy scale with picombo. 
 (A) Distribution of early (31 total, light grey dots) and late (50 total, dark grey dots) 
mouse and human (9 total, open circles) DBS parameters. (B) Instantaneous velocity 
during stimulation for parameters within the indicated picombo ranges. Dark lines indicate 
averages, while lighter shadings indicate +/- SEM. (C) Correlation of velocity with picombo 
(50 conditions, N=9) in late DBS (~2 months after early DBS). (D) Correlation of 
average AIM score with picombo (50 conditions, N=9). N=mice. Each point represents an 
average across subjects and trials for a given condition. 
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Supplemental Figure 2.3 
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Supplemental Figure 2.3. Modeling DBS using picombo predicts the therapeutic 
parameter space. 
(A) 3-D representation of STN DBS parameter space based on the early regression 
generated from data in Figure 2.3E. (B-D) Cross-sections of STN DBS parameter space 
from (A) at constant current (B), pulse width (C), and frequency (D). (E) 3-D 
representation of STN DBS parameter space based on the late regression generated 
from data in Supplemental Figure 2.2C. (F-H) Cross-sections of STN DBS parameter 
space from (E) at constant current(F), pulse width (G), and frequency (H). 
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Supplemental Figure 2.4 
 
Supplemental Figure 2.4. Movement velocity and dyskinesia relationships to 
picombo by stimulation sites across individual mice. 
(A) Correlations between velocity and picombo in two sample mice (31 conditions) 
illustrating differences in the slope of the correlation (vel slope). (B) Correlation between 
dorsoventral (DV) stimulation location and vel slope across individual mice (N=9). (C) 
Correlation between the stimulation site-pyramidal tract distance and dysk slope across 
individual mice (N=9). (D) Correlation between vel slope and dysk slope across 
individual mice (N=9). N=mice. 
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Supplemental Table 2.1 
Supplemental Table 2.1. Early DBS Parameters.  
Table showing the parameters used for early DBS testing. 
 
Current 
(µA) 
Frequency 
(Hz) 
Pulse Width 
(µs) 
100 100 40 
100 120 60 
100 120 120 
150 120 60 
175 20 50 
175 40 50 
200 5 60 
200 10 60 
200 10 120 
200 15 60 
200 20 60 
200 40 60 
200 60 60 
200 60 100 
200 80 60 
200 100 60 
200 120 20 
200 120 40 
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Current 
(µA) 
Frequency 
(Hz) 
Pulse Width 
(µs) 
200 120 60 
200 160 60 
200 180 60 
225 80 80 
250 10 60 
250 60 40 
250 140 70 
300 5 120 
300 10 60 
300 10 120 
400 1 120 
0 0 0 
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Supplemental Table 2.2 
Supplemental Table 2.2. Late DBS Parameters.  
Table showing the parameters used for late DBS testing. 
 
Current 
(µA) 
Frequency 
(Hz) 
Pulse Width 
(µs) 
10 88 46 
10 170 113 
13 19 99 
35 100 116 
42 84 110 
83 109 115 
100 10 30 
100 10 60 
100 10 90 
100 10 120 
100 120 30 
100 120 90 
102 117 27 
118 131 20 
147 89 78 
150 10 30 
150 10 60 
150 10 90 
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Current 
(µA) 
Frequency 
(Hz) 
Pulse Width 
(µs) 
150 10 120 
150 120 90 
150 120 120 
200 10 30 
200 10 90 
200 120 30 
200 120 90 
204 131 19 
204 152 89 
209 63 114 
212 6 33 
213 151 33 
230 159 22 
238 192 79 
245 182 15 
250 10 30 
250 10 90 
250 10 120 
250 120 30 
250 120 60 
250 120 90 
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Current 
(µA) 
Frequency 
(Hz) 
Pulse Width 
(µs) 
250 120 120 
288 97 96 
290 31 117 
300 10 30 
300 10 90 
300 120 30 
300 120 60 
300 120 90 
300 120 120 
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Supplemental Table 2.3 
Supplemental Table 2.3. Human DBS Parameters.  
Table showing the parameters used in human DBS testing. 
 
Voltage 
(V) 
Frequency 
(Hz) 
Pulse Width 
(µs) 
1 155 65 
2 155 65 
3.1 5 65 
3.1 50 65 
3.1 130 65 
3.1 185 65 
0 0 0 
3.5 155 65 
3.1 155 60 
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Chapter 3: 
Levodopa and STN Deep Brain Stimulation Relieve 
Parkinsonian Motor Symptoms with Opposing 
Changes in Basal Ganglia Activity‡ 
 
 
 
 
 
 
 
 
‡A version of this chapter is currently in submission as Schor JS, Gonzalez Montalvo I, 
Spratt PWE, Brakaj RJ, Bender KJ, and Nelson AB. Levodopa and STN Deep Brain 
Stimulation Relieve Parkinsonian Motor Symptoms with Opposing Changes in Basal 
Ganglia Activity. 
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Levodopa and STN Deep Brain Stimulation Relieve 
Parkinsonian Motor Symptoms with Opposing Changes in 
Basal Ganglia Activity 
Abstract 
 Levodopa and subthalamic nucleus deep brain stimulation (STN DBS) are two 
common treatments for the motor symptoms of Parkinson’s disease (PD). While both 
treatments had been hypothesized to inhibit basal ganglia output activity, it is currently 
unknown whether they act through similar or distinct mechanisms. To investigate these 
two possibilities, we performed calcium imaging in parkinsonian mice during treatment 
with levodopa and STN DBS. Using this approach, we found, as predicted, that levodopa 
inhibits activity in the substantia nigra pars reticulata (SNr). However, we found that STN 
DBS increases activity in the STN and SNr. Furthermore, both optical inhibition of SNr 
neurons and excitation of STN neurons provide behavioral benefits that mirror those of 
levodopa and STN DBS, respectively. Together, these results suggest bidirectional 
changes in basal ganglia activity can alleviate PD motor symptoms, which may both refine 
basal ganglia models and inform development of new neuromodulatory therapies. 
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Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of 
midbrain dopamine neurons, and manifests with profound motor deficits such as 
bradykinesia and tremor. PD patients are often treated with either dopamine replacement 
therapy (e.g. the dopamine precursor levodopa), subthalamic nucleus deep brain 
stimulation (STN DBS), or a combination of the two. While both levodopa and STN DBS 
can relieve motor symptoms, our ability to improve either treatment modality, or to assess 
their potential for treating other diseases, is hampered by a lack of understanding of their 
underlying mechanisms of action. 
Both levodopa and STN DBS are hypothesized to modify neural activity in the 
basal ganglia, a series of interconnected subcortical nuclei whose function is known to be 
disrupted in PD. Traditional models of the basal ganglia posit that loss of dopaminergic 
input to the basal ganglia in PD leads to increased activity in the basal ganglia output 
nuclei (globus pallidus pars interna, GPi; substantia nigra pars reticulata, SNr) and 
reduced movement1,2. These models also predict hyperactivity in the major excitatory 
input to GPi/SNr, the STN. This hypothesis has largely been borne out in both PD patients 
and animal models of PD, though some exceptions do exist3. 
Dopamine replacement therapy is hypothesized to normalize basal ganglia 
function by decreasing activity at the level of both STN and GPi/SNr. Single-unit 
electrophysiology in GPi/SNr of rodents, non-human primates (NHPs), and humans have 
largely reinforced this notion4–7. However, electrophysiological studies of the STN have 
been far more variable, showing increases8, decreases9, or no change in activity in 
response to dopamine replacement10. 
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Initially, STN DBS was also thought to act by inhibiting basal ganglia activity. As it 
had long been known that STN lesions were therapeutic in PD11,12, STN DBS was 
developed as a “reversible lesion”. However, whether STN DBS actually inhibits basal 
ganglia activity has become increasingly unclear. One reason for this is that performing 
electrical recordings of neural activity during STN DBS is technically challenging, due to 
the large electrical artifacts produced during high-frequency electrical stimulation. These 
artifacts may obscure the accurate measurement of firing in highly active basal ganglia 
nuclei such as the STN, GPi, and SNr. Across multiple experimental preparations, 
investigators have proposed several different effects of STN DBS13. For instance, while 
some groups have reported the predicted inhibitory effects of STN DBS on STN and 
GPi/SNr14,15, others have observed excitation16,17. In fact, some have suggested that DBS 
acts on distant brain regions, such as the motor cortex, by antidromic stimulation. Using 
optogenetic DBS, these groups have found that optical stimulation of “hyperdirect” M1 
neurons that project to the STN can relieve motor symptoms in parkinsonian mice18,19. 
These conflicting findings highlight the need to understand how electrical DBS impacts 
neural activity. 
Here, we use region- and cell-type specific optical recording methods in an 
established mouse model of PD to directly compare the effects of levodopa and electrical 
STN DBS on activity in STN, SNr, and hyperdirect M1 neurons. As in humans, we find 
that both levodopa and STN DBS improve slowing of movement, or bradykinesia, in the 
mouse model. As predicted, levodopa inhibits activity at the level of basal ganglia output 
(SNr). STN DBS, however, increases activity in both the STN and SNr. Furthermore, 
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optical inhibition of SNr and optical excitation of STN, which mimic the most salient effects 
of levodopa and STN DBS, respectively, improve bradykinesia in parkinsonian mice. 
Taken together, these results suggest these two therapies act through distinct and 
seemingly opposing neural mechanisms. 
Results 
Both Levodopa and STN DBS relieve parkinsonism in mice 
While levodopa and STN DBS have been utilized in several animal models of PD, their 
behavioral effects have not been directly compared in mice. We used the unilateral 6-
OHDA mouse model of PD, which in our previous work shows reduced movement velocity 
(~1 cm/s vs ~4 cm/s in healthy controls) and an ipsilesional rotational bias20. To test 
whether levodopa and STN DBS similarly improve movement parameters, we measured 
the open-field locomotion and rotational bias of 6-OHDA-treated mice during 
administration of either levodopa (5 mg/kg i.p.) or electrical STN DBS (bipolar, biphasic 
stimulation at 60 or 100 Hz with a 60 µs pulse-width and an amplitude of 200 µA). 
Levodopa reliably increased movement velocity (Figure S3.1A-C; N=32, LD vs pre/post: 
p<0.001) and produced a contralesional rotation bias (Figure S3.1D; LD vs pre/post: 
p<0.001). Additionally, in a minority of mice, levodopa evoked moderate dyskinesias 
(Figure S3.1E; AIM score 0.66 ± 0.2), as has been previously reported21. Similarly, STN 
DBS at either 60 Hz (Figure S3.1F-H; N=39 mice) or 100 Hz (Figure S3.1K-M; N=36 mice) 
increased movement velocity (stim vs pre/post: p<0.001) and evoked moderate 
dyskinesias in a minority of mice (Figure S3.1J,O). However, no contralesional rotation 
bias was seen with STN DBS at either 60 Hz (stim vs pre/post: p=0.72/0.77) or 100 Hz 
(stim vs pre/post: p=0.84/0.63). Together, these results indicate that both levodopa and 
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STN DBS are therapeutic in parkinsonian mice, producing broadly similar effects on 
movement, with the notable exception of rotational behavior.  
STN DBS consistently increases STN activity 
While treatment with levodopa and STN DBS evoked similar changes in motor behavior 
in parkinsonian mice, it is unknown whether they drive similar changes in STN activity. 
To compare the effect of levodopa and STN DBS on neural activity in the STN while 
minimizing DBS-related artifacts, we used calcium signals as a proxy for neural activity. 
We recorded bulk changes in the fluorescence of GCaMP6s, a genetically encoded 
calcium indicator. To target glutamatergic neurons within STN, we injected parkinsonian 
VGlut2-Cre mice with AAVs encoding Cre-dependent GCaMP6s, and then implanted 
mice with both an STN DBS device and an optical fiber (Figure 3.1A-B). We then 
measured changes in STN activity in vivo in response to treatment with levodopa or STN 
DBS. As in the larger cohort, levodopa increased movement velocity and evoked 
contralesional rotations in VGlut2-Cre mice (Figure 3.1C-D, S3.2A,D; N=9). In these 
sessions, STN activity overall was not significantly changed, decreasing in some sessions 
and increasing in others (Figure 3.1C-D, S3.2A; LD vs pre/post: p=0.90/0.83). Injection 
with saline did not produce significant changes in STN activity (N=9 mice, saline vs 
pre/post: p=0.053/ p=0.97), nor did it increase velocity or produce significant changes to 
rotation bias (Figure S3.2E).These levodopa findings, while not consistent with rate model 
predictions, do correspond to the variable changes seen by other groups. 
We next tested whether STN DBS would produce similar changes in STN neural 
activity. In the same mice, we performed electrical STN DBS at either 60 or 100 Hz, which 
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increased movement velocity as previously observed (Figure 3.1E-H, S3.2B-D). 
Surprisingly, STN DBS caused a significant increase in STN calcium signals (Figure 3.1E-
H, S3.2B-C; N=9 mice, stim vs pre/post: p<0.001). This result suggests that, contrary to 
classical models, neither levodopa nor STN DBS reliably inhibit STN activity, and 
moreover that STN DBS may increase STN activity. 
One potential explanation for these surprising findings is that GCaMP calcium 
signals do not correlate with spiking activity in the high-firing STN. To examine how 
spiking relates to STN GCaMP signals, we performed simultaneous whole-cell current-
clamp recordings and fluorescence imaging of STN neurons in ex vivo slices from VGlut2-
Cre mice injected with GCaMP6s (Figure S3.2F,J; n=5 cells, N=2 mice). Neurons were 
stimulated in 1-minute epochs with current pulses at a range of frequencies, or constant 
current (Figure S3.2G). STN neurons showed rhythmic spiking that corresponded to the 
frequency of pulsatile stimulation (Figure S3.2H-I). Calcium, as measured by changes in 
GCaMP6s fluorescence, similarly increased during both 10 Hz and 50-60 Hz stimulation 
but did not increase further during 100-120 Hz stimulation (Figure S3.2K-L). These 
findings suggest a correlation between STN firing rates and calcium signals up to 60 Hz 
stimulation, and a plateau in GCaMP signal at 100-120 Hz. In response to constant 
current stimulation, STN neurons fired only transiently, appearing to enter depolarization 
block (Figure S3.2H-I). Under these circumstances, evoked calcium signals fell between 
those evoked by 10 and 50-60 Hz stimulation (Figure S3.2K-L). These experiments 
suggest that the relationship between spiking and GCaMP calcium signals may break 
down at very high frequencies of stimulation, or under conditions of forced depolarization 
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block. However, at the more moderate frequencies explored here (60 Hz), GCaMP 
calcium signals retain a correlation to STN firing. 
STN DBS and levodopa have opposite effects on basal ganglia output 
Though the STN is a critical node within the basal ganglia circuit, especially in regard to 
dysfunction in PD and its treatment, changes in STN activity are believed to regulate 
motor function via excitatory projections to basal ganglia output nuclei. To assess 
treatment-evoked changes in activity at the level of basal ganglia output (in rodents, the 
SNr), we expressed GCaMP6s and implanted optical fibers in the SNr of parkinsonian 
mice. We either injected VGAT-Cre mice with Cre-dependent GCaMP6s (N=6 mice) or 
WT mice with synapsin-dependent GCaMP6s (Figure 3.2A; N=2 mice). As previously, 
levodopa evoked an increase in movement velocity and a contralesional rotation bias 
(Figure 3.2B-C, S3.3A,D). In parallel, we observed a significant decrease in SNr neural 
activity (Figure 3.2B-C, S3.3A; N=8 mice, LD vs pre/post:p<0.001). Saline injection did 
not significantly change SNr calcium signals (Figure S3.3E; N=8, saline vs pre/post: 
p=0.31/0.96), nor did it increase movement velocity or significantly change rotation bias 
(Figure S3.3E).  These findings support rate-model predictions, as well as prior 
experimental data, that dopamine replacement therapy inhibits basal ganglia output 
activity. 
We then tested whether similar changes could be observed in the SNr during 
therapeutic STN DBS. As before, STN DBS increased movement velocity (Figure 3.2D-
G, S3.3B-D). However, in contrast to levodopa, STN DBS (at both 60 and 100 Hz) 
increased SNr activity (Figure 3.2D-G, S3.3B-C; N=7 mice, stim vs pre/post: p<0.001). 
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Thus, while both levodopa and STN DBS produced similar therapeutic increases in 
movement velocity, the two treatments evoked opposing changes in SNr activity. 
STN DBS variably changes in hyperdirect M1 neural activity 
Another group of neurons which have been implicated in the therapeutic mechanisms of 
STN DBS is the hyperdirect pathway: primary motor cortex (M1) neurons that project 
monosynaptically to the STN. To assess changes in the activity of hyperdirect M1 neurons 
in response to levodopa and STN DBS, we used a retrograde viral strategy. We injected 
the STN of parkinsonian mice with one of two retrograde viruses encoding Cre 
recombinase (CAV2-Cre or rAAV2-Cre-mCherry), and injected M1 with Cre-dependent 
GCaMP6s. This strategy restricted expression of GCaMP6s to only STN-projecting M1 
neurons. We then implanted an optical fiber in M1 and a DBS device in the STN (Figure 
3.3A). We first administered levodopa, which increased movement velocity and rotational 
behavior (Figure 3.3B-C, S3.4A,D). During these sessions, hyperdirect M1 activity did not 
significantly change from baseline (Figure 3.3B-C; S3.4A; N=8, LD vs pre: p=0.078). 
Injection with saline (N=8 mice) did not significantly alter movement parameters, nor 
change hyperdirect M1 activity (Figure S3.4E; saline vs pre/post: p=1.0/0.72). These 
findings suggest that the behavioral effects of levodopa are not accompanied by 
significant modulation of hyperdirect M1 neurons. 
As it has been suggested that antidromic activation of hyperdirect M1 neurons may 
play a role in the therapeutic response to STN DBS, we next examined whether STN DBS 
modulates hyperdirect M1 activity. As in other experiments, both 60 and 100 Hz 
stimulation consistently increased movement velocity (Figure 3.3D-E, S3.4B,D). During 
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60 Hz STN DBS, hyperdirect M1 calcium responses were surprisingly variable: just under 
half of the mice showed a decrease in hyperdirect M1 activity, and the rest showed either 
increases or no change (Figure 3.3D-E,H, S3.4B; stim vs pre/post: p=0.084/0.11). In the 
same mice, 100 Hz stimulation produced similar increases in movement velocity, but 
evoked more consistent increases in M1 activity (Figure 3.3F-H, S3.4C; N=8, stim vs 
pre/post: p<0.001). Given this seeming lack of correlation between hyperdirect M1 activity 
and the behavioral benefits of STN DBS, we wondered if the movement velocity of a 
single mouse during 60 Hz STN DBS could be predicted by whether that mouse showed 
increased or decreased M1 activity. Interestingly, movement velocity during stimulation 
was uncorrelated with the directionality of neural activity in M1 (R2=-0.14, p=0.96). These 
findings suggest that while certain stimulation parameters may engage hyperdirect 
pathway activity, these changes do not correlate strongly with behavioral improvements 
during DBS. 
During STN DBS, changes in hyperdirect M1 activity occur much more slowly than 
changes in either STN activity, SNr activity, or movement velocity 
While only one of the three regions we recorded from showed significant responses to 
levodopa, all three regions showed significant changes to STN DBS for at least one 
stimulation frequency. Neurons that represent strong candidates in mediating the 
therapeutic effects of STN DBS would be predicted to show changes in activity on the 
timescale of behavioral benefits. In order to further explore how changes in neural activity 
correspond to changes in movement velocity, we measured the rise time of the calcium 
signal obtained in those brain regions and conditions in which we observed significant 
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changes in neural activity: STN (60 and 100 Hz), SNr (60 and 100 Hz), M1 hyperdirect 
(100 Hz). Given the observed lag between electrophysiology and bulk GCaMP signals22, 
we would expect that even changes in neural activity that drive behavior might appear to 
lag the behavior itself. Across all STN DBS conditions, the rise time for movement velocity 
averaged 2.84 ± 0.57 sec. For each condition, we calculated the difference in rise time 
for the calcium signal and movement velocity, as an indicator of whether these two signals 
changed on a similar timescale. The rise time of STN calcium signals during 60 Hz or 100 
Hz STN DBS lagged velocity rise time by 2.56 ± 1.14 sec (Figure S3.2B-C). We observed 
a similarly short lag comparing SNr calcium signals to the corresponding movement 
velocity traces (3.71 ± 1.77 sec; S3B-C). However, the lag in hyperdirect M1 activity was 
markedly longer (17.25 ± 3.05 sec; S4B-C). Comparing these kinetics, changes in STN 
and SNr activity are stronger candidates than M1 hyperdirect activity in contributing to the 
therapeutic effects of STN DBS. 
Optogenetic inhibition of SNr neurons or optogenetic activation of STN neurons 
increases movement in parkinsonian mice 
Contrary to rate-based predictions regarding changes in neural activity in response to 
antiparkinsonian treatments, we observed distinct, and sometimes opposing, changes in 
neural activity in response to levodopa and STN DBS. Treatments may evoke some  
changes in neural activity that drive motor improvement, while others changes may be 
correlated but not causal. To address this potential difference, we next tested whether 
manipulating neural activity, in the absence of levodopa or STN DBS, might be sufficient 
to improve movement velocity. The most salient effect of levodopa was to suppress SNr 
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activity. To simulate this effect, we injected parkinsonian VGAT-Cre mice with Cre-
dependent halorhodopsin or eYFP (control) in the SNr (Figure 3.4A). To validate 
halorhodopsin function in SNr neurons, we performed cell-attached recordings in ex vivo 
slices (Figure 3.4B; n=17 cells, N=3 mice). As in vivo, SNr neurons fired spontaneously 
(Figure 3.4C). In response to one-minute periods of green light (6 mW), SNr neurons 
showed a significant decrease in firing rate (Figure 3.4C-D, S3.5A; stim vs pre/post: 
p<0.001). We then assessed motor behavior in response to one-minute epochs of green 
light (6 mW) in vivo. Optical inhibition of SNr activity increased movement velocity (Figure 
3.4E-F, S3.5B; N=10; stim vs pre/post: p<0.001) and contralesional rotations (Figure 
3.4G; stim vs pre/post: p<0.001), mimicking behavioral effects of levodopa administration. 
No change was seen in the behavior of eYFP-expressing mice in response to green light 
(Figure S3.5E; N=7 mice, stim vs pre/post: p=0.98/0.93). This result suggests that 
decreasing SNr activity is sufficient to increase movement in parkinsonian mice, and 
moreover may be a therapeutic mechanism of levodopa. 
The most prominent effect of STN DBS in our experiments was an increase in STN 
calcium signals. To test whether this increase in STN activity was sufficient to produce 
therapeutic effects in parkinsonian mice, we injected VGlut2-Cre mice with Cre-
dependent channelrhodopsin or eYFP (control) in the STN (Figure 3.4H). To validate the 
effects of channelrhodopsin on STN neural activity, we performed cell-attached 
recordings in ex vivo slices (Figure 3.4I; n=13 cells, N=3 mice). As in vivo, STN neurons 
fired spontaneously (Figure 3.4J). As predicted, STN neurons showed a significant 
increase in firing rate in response to one-minute epochs of pulsatile blue light stimulation 
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(Figure 3.4J-K; 50 Hz, 3 mW; stim vs pre/post: p<0.05), though the firing rate waned over 
the course of stimulation (Figure S3.5C). We then assessed the behavioral effects of 
pulsatile blue light stimulation (50 Hz, 3 mW) in vivo. Similar to electrical STN DBS, blue 
light stimulation increased movement velocity (Figure 3.4L-M, S5D; N=8, stim vs pre/post: 
p<0.001), but did not evoke a contralesional rotation bias (Figure 3.4N). Interestingly, 
movement velocity tended to peak early during stimulation, and fall off to a lower level 
(Figure S3.5D), similar to the firing rate decline observed during cell-attached recordings. 
Mice expressing eYFP (N=9 mice) did not show a significant change in movement velocity 
during blue light stimulation (Figure S3.5F; stim vs pre/post: p=0.81/0.82). Taken 
together, these results indicate that both inhibition of the SNr and excitation of the STN 
increase movement velocity in parkinsonian mice. Therefore, the seemingly paradoxical, 
opposing changes in activity evoked by levodopa and electrical STN DBS may in fact 
both contribute to the therapeutic effects on motor behavior. 
Discussion 
We combined a recently developed mouse model of electrical STN DBS for Parkinson’s 
disease20 with electrical artifact-free GCaMP fiber photometry to compare the effects of 
levodopa and STN DBS on neural activity. While both levodopa and STN DBS similarly 
relieved bradykinesia, they had distinct, and in some cases opposing, effects on basal 
ganglia neural activity. Furthermore, optical manipulations that mimicked the effects of 
levodopa and STN DBS on neural activity both relieved bradykinesia, despite driving it in 
opposite directions. 
In this study, we used calcium imaging with GCaMP6s to examine how neural 
activity changes during treatment with levodopa and STN DBS. To our knowledge, this is 
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one of the first studies to use calcium imaging with electrical STN DBS in vivo in 
parkinsonian animals. This approach had several advantages, as well as limitations. The 
key advantage was the ability to obtain recordings free from electrical artifacts. This had 
been a major obstacle in prior electrophysiological studies, particularly in studying the 
effect of DBS on the neurons in the target structure, such as the STN or GPi. A second 
advantage was the ability to use cell type- or projection-specific techniques in targeting 
neurons for imaging. For example, the use of retrograde viruses allowed us to target the 
direct projections from primary motor cortex to STN (hyperdirect pathway), a population 
of significant interest in PD and DBS. Though STN and SNr are relatively homogeneous 
structures, with regard to major neurotransmitters23,24, future studies could use GCaMP 
and genetics to target either specific STN/SNr projections, or novel cell types within 
them25,26. A disadvantage of our approach over traditional electrophysiology, however, is 
its temporal resolution. While extracellular electrophysiology can detect individual action 
potentials, calcium imaging with GCaMP likely integrates calcium over multiple spikes27. 
Fiber photometry further averages across a population of neurons, making it hard to 
detect rapid events or patterned activity. Nonetheless, given that our assessments of 
neural activity with photometry match those obtained with single-unit electrophysiology 
during levodopa treatment, there appears to be correspondence between the two 
recording techniques. In the future, voltage indicators with high signal-to-noise that are 
compatible with deep imaging, as well as miniscope imaging of many single neurons 
simultaneously, might allow detection of single spikes and help increase the information 
obtained in optical recordings during DBS. 
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On the whole, our reported effects of levodopa on neural activity support traditional 
models of basal ganglia function. We observed significant decreases in SNr activity in 
parallel with the therapeutic effects of levodopa, as has been seen in previous 
electrophysiological studies in humans, NHPs, and rats6,7,28. Interestingly, we did not see 
consistent changes in STN or M1 hyperdirect activity in response to levodopa, though we 
cannot rule out small changes that could not be detected with our methods or our sample 
size. The STN result does not conform to predictions of the rate model, but is consistent 
with the variety of responses reported in previous studies8–10. Little in the literature 
suggests how levodopa might impact hyperdirect M1 neurons. 
However, our observation that therapeutic STN DBS increased activity at the level 
of the STN and SNr is at odds with rate-based models of basal ganglia function. 
Additionally, our data conflicts with some previous electrophysiological studies in 
primates14,15, but corresponds well to other studies16,17,29. Some discrepancies in existing 
physiological data may arise from electrical artifact removal from electrophysiological 
recordings, especially in structures like STN and SNr that have high spontaneous firing 
rates. Other discrepancies may relate to differences among animal models of PD.  
Though we observed modulation of hyperdirect M1 neurons during STN DBS, this 
modulation did not correlate well with therapeutic effects. This disconnect has a number 
of potential explanations. Importantly, while past mouse studies have used optogenetic 
stimulation as a proxy for electrical STN DBS18,19, we used electrical stimulation in an 
effort to more closely model what is observed in PD patients. The former approach 
identifies manipulations which are sufficient to relieve parkinsonian motor symptoms, 
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while the latter identifies changes that correlate with a specific therapy. Thus, while 
optogenetic stimulation may reveal that changing neural activity in a variety of ways can 
relieve parkinsonism in mice, it is difficult to extrapolate which of these changes actually 
occur during electrical STN DBS. For instance, though our optogenetic experiments show 
that both inhibition of the SNr and excitation of the STN are therapeutic in parkinsonian 
mice, we only observe STN excitation during electrical STN DBS. In agreement with our 
findings in hyperdirect M1 neurons, a recent NHP study found that while some cortical 
neurons do show antidromic activation during STN DBS, cortical changes are inconsistent 
between animals and do not match the timescale of behavioral change30. 
We found that therapeutic interventions produced both decreases (levodopa) or 
increases (STN DBS) in STN and/or SNr activity, and moreover that reproducing these 
changes with optical methods could also relieve parkinsonian motor deficits. These 
findings are at odds with the classical model of basal ganglia function, but are not without 
precedent. Indeed, recent chemogenetic and optogenetic studies indicate that activating 
or inhibiting STN neurons can relieve motor symptoms in parkinsonian mice31–33. Why 
might rate changes in either direction produce therapeutic effects? One possible 
explanation is that rate-independent aspects of neural activity, such as within-neuron 
firing pattern or between-neuron synchronization, may drive PD symptoms and represent 
key markers of therapeutic interventions, as has been postulated previously34–36. Many 
other groups have observed increased oscillations throughout the basal ganglia in 
parkinsonian animal models and in humans, which may resolve with therapeutic 
treatment37–40. If this is the case, though levodopa and STN DBS may drive opposing 
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changes in firing rate, they may both interrupt the pathological rhythmicity observed in 
PD. This possibility might be investigated in the future using a combination of optical and 
electrical methods, building on the approach introduced here. 
Excitingly, our observation that bidirectional changes in basal ganglia activity 
confer therapeutic benefit in a mouse model of PD suggests a wider therapeutic space 
for the treatment of PD. Most therapeutic approaches to PD have been predicated on the 
idea that inhibition of hyperactive basal ganglia nuclei is required for therapeutic benefit, 
but we now know that both increases and decreases in activity can improve movement. 
In addition, our work linking neural activity to behavior in STN DBS for PD may inform the 
application of DBS to other neuropsychiatric disorders. To rationally apply DBS to other 
conditions, such as addiction or Tourette’s syndrome, it is critical to know how electrical 
stimulation might impact the underlying neural circuitry of disease. 
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Methods 
Animals 
3-6-month-old wild-type and transgenic C57Bl/6 mice of either sex were used in this 
study. To allow optical recording and manipulation of glutamatergic STN neurons, 
homozygous VGlut2-Cre mice (Stock No. 028863, Jackson Labs) were bred to wild-type 
C57BL/6 mice (Jackson Labs) to yield hemizygous VGlut2-Cre mice. To allow optical 
recording and manipulation of GABAergic SNr neurons, homozygous VGAT-Cre mice 
(Jackson Labs) were bred to wild-type C57BL/6 mice (Jackson Labs) to yield hemizygous 
VGAT-Cre mice. Animals were house 1-5 per cage on a 12-hour light/dark cycle with ad 
libitum access to rodent chow and water. All behavioral manipulations were performed 
during the light phase. We complied with local and national ethical regulations regarding 
the use of mice in research. All experimental protocols were approved by the UC San 
Francisco Institutional Animal Care and Use Committee. 
Surgical Procedures 
Stereotaxic surgery was performed between 3 and 6 months of age. Anesthesia was 
induced with intraperitoneal (IP) injection (0.1 mL) of ketamine (40 mg/kg) and xylazine 
(10 mg/kg) and maintained with inhaled isoflurane (0.5%-1%). To model Parkinson’s 
disease in mice, the neurotoxin 6-hydroxydopamine (6-OHDA, 1 µL, 5 mg/mL) was 
injected unilaterally in the left medial forebrain bundle (MFB, -1.0 AP, -1.0 ML, 4.9 DV). 
Desipramine (0.2 mL, 2.5 mg/mL) was injected intraperitoneally (IP) approximately 30 
min prior to 6-OHDA injections to reduce uptake by other monoaminergic neurons in the 
MFB. Additional surgeries were performed at least two weeks following MFB injection.  
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For experiments involving electrical STN DBS, a 3-lead bipolar stimulating 
electrode array was implanted in the ipsilesional STN (-1.8 AP, -1.65 ML, 4.5 DV) 20. 
During the same surgery, VGlut2-Cre mice were injected with Cre-dependent AAV1-Syn-
Flex-GCaMP6s-WPRE-SV40 (UPenn, 100 nL) in the STN (-1.8 AP, -1.65 ML, 4.5 DV) 
and implanted with a photometry fiber-optic ferrule (0.4 mm, Doric Lenses) above the 
STN (4.3 DV). VGAT-Cre mice were injected with the Cre-dependent GCaMP6s vector 
(300-500 nL) in the SNr (-3.2 AP, -1.6 ML, 4.5 DV) and implanted with a fiber-optic ferrule 
above the SNr (4.3 DV). Wild-type mice were injected with a retrograde virus encoding 
Cre recombinase [either CAV-Cre (Montpellier, 100 nL) or AAV2retro-Cre-mCherry 
(Addgene/UPenn Vector Core, 100 nL)] in the STN (-1.8 AP, -1.65 ML, 4.5 DV) and Cre-
dependent GCaMP6s (500 nL) in the primary motor cortex (M1, +2 AP, -1.56 ML, 1 DV) 
and implanted with a fiber-optic ferrule above M1 (0.8 DV). 
For optical stimulation experiments, VGlut2-Cre mice were injected with Cre-
dependent AAV5-DIO-ChR2-eYFP (UPenn, diluted 1:2 in normal saline, 100 nL) or 
AAV5-DIO-eYFP (UNC, 100 nL) and implanted with a fiber-optic ferrule (0.2 mm, Thor 
Labs) above the STN (4.3 DV). VGAT-Cre mice were injected with Cre-dependent AAV5-
DIO-eNpHR3.0-eYFP (UNC Vector Core, 300 nL) or AAV5-DIO-eYFP (UNC, 300 nL) and 
implanted with a fiber-optic ferrule (0.2 mm, Thor Labs) above the SNr (4.3 DV). 
A minimum of 3 weeks of viral expression was allowed before behavioral testing. 
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Behavior 
All behavior was conducted in the open field (clear acrylic cylinders, 25 cm diameter) 
following 1 day of habituation (20 minutes). Mice were monitored via two cameras, one 
directly above and one in front of the chamber. Video-tracking software (Noldus 
Ethovision) was used to quantify locomotor activity, including movement velocity, 
ipsilateral rotations, and contralateral rotations. Dyskinesia was scored manually by an 
unblinded rater using a modified version of the abnormal involuntary movements (AIM) 
scoring method 21. Dyskinesia was quantified in one-minute increments either every 
minute (for STN DBS experiments) or every 5 minutes (for levodopa experiments), with 
axial, limb, and orofacial body segments rated on a scale of 0-3 each. A score of 0 
indicates no abnormal movement, while a score of 3 indicates continuous dyskinesia for 
the one minute epoch. The scores for each body segment are then summed, with a 
maximum score of 9 per epoch. 
Pharmacology 
6-OHDA (Sigma Aldrich) was prepared at 5 mg/mL in normal saline. Levodopa was 
prepared (0.5 mg/mL Sigma Aldrich) with benserazide (0.25 mg/mL, Sigma Aldrich) in 
normal saline and always administered at 5 mg/kg. 
Electrical Stimulation 
An isolated constant current bipolar stimulator (WPI) was used to deliver electrical stimuli. 
The timing of stimuli was controlled by TTL input from an Arduino. Electrical stimulation 
experiments consisted of five 1 min stimulation periods, each preceded and followed by 
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1 min of no stimulation, for a total of 11 min. Both the construction of STN DBS electrodes 
and the determination of optimal stimulation electrode pair were as detailed previously 20. 
Fiber Photometry 
Fiber photometry signals were acquired through implanted 400 µm optical fibers, using 
an LED driver system (Doric). Following signal modulation, 405 nm (control signal, from 
GCaMP autofluorescence) and 465 nm signals were demodulated via a lock-in amplifier 
(RZ5P, TDT), visualized, and recorded (Synapse, TDT). Offline, the 405 nm signal was 
fit to the 465 nm signal using a first-degree polynomial fit (Matlab) to extract the non-
calcium dependent signal (due to autofluorescence, fiber bending, etc). This was then 
subtracted from the 465 nm signal to generate a motion-corrected signal. To remove the 
gradual, slow bleaching observed in the ~3 hour saline and levodopa recordings, we 
additionally fit a double exponential to the 405 nm signal, linearly fit it to the the motion-
corrected signal, and then subtracted it. 
Every processed fiber photometry signal was normalized (z-scored) by subtracting 
the mean and dividing by the standard deviation of the closest preceding “pre” period. For 
electrical stimulation experiments, the 30 seconds preceding each stimulation period was 
used to normalize the subsequent 1-min stim and 1-min post period. For levodopa and 
saline experiments, the 20 minutes prior to injection was used to normalize the 
subsequent 2.5 hours of signal. 
Ex vivo Slice Electrophysiology and Imaging 
To prepare ex vivo slices for whole-cell recordings and GCaMP imaging, mice were 
deeply anesthetized with IP ketamine-xylazine, transcardially perfused with ice-cold 
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glycerol-based slicing solution, decapitated, and the brain was removed. Glycerol-based 
slicing solution contained (in mM): 250 glycerol, 2.5 KCl, 1.2 NaH2PO4, 10 HEPES, 21 
NaHCO3, 5 glucose, 2 MgCl2, 2 CaCl2. The brain was mounted on a submerged chuck, 
and sequential 275 mm coronal or sagittal slices were cut on a vibrating microtome 
(Leica), transferred to a chamber of warm (34°C) carbogenated ACSF containing (in mM) 
125 NaCl, 26 NaHCO3, 2.5 KCl, 1 MgCl2, 2 CaCl2, 1.25 NaH2PO4, 12.5 glucose for 30-
60 min, then stored in carbogenated ACSF at room temperature. Each slice was then 
submerged in a chamber superfused with carbogenated ACSF at 31°C-33°C for 
recordings. STN or SNr neurons were targeted using differential interference contrast 
(DIC) optics in VGlut2-Cre or VGAT-Cre mice, respectively, on an Olympus BX 51 WIF 
microscope. 
For opsin validation experiments, neurons were patched in the cell-attached 
configuration using borosilicate glass electrodes (3-5 MOhms) filled with ACSF. Picrotoxin 
was added to all external solutions for opsin validation. For combined electrophysiology-
imaging experiments with GCaMP6s, neurons were patched in the whole-cell current-
clamp configuration using borosilicate glass electrodes (3-5 MOhms) filled with potassium 
methanesulfonate-based internal solution containing (in mM): 130 KMeSO3, 10 NaCl, 2 
MgCl2, 0.16 CaCl2, 0.5 EGTA, 10 HEPES, 2 MgATP, 0.3 NaGTP, pH 7.3. All recordings 
were made using a MultiClamp 700B amplifier (Molecular Devices) and digitized with an 
ITC-18 A/D board (HEKA). Data were acquired using Igor Pro 6.0 software (Wavemetrics) 
and custom acquisition routines (mafPC, courtesy of M. A. Xu-Friedman). Recordings 
were filtered at 5 kHz and digitized at 10 kHz.  
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To validate ChR2 or eNpHR3.0 function in slice, light pulses were delivered to the 
slice by a TTL-controlled LED (Olympus), passed through a GFP (473 nm) or TxRed (562 
nm) filter (Chroma) and the 40X immersion objective. LED intensity was adjusted to yield 
an output of either 3 mW (for ChR2) or 6 mW (for eNpHR3.0) at the slice. Light was 
delivered in 1 minute epochs, at 50 Hz, 3 ms pulse width (for ChR2) or continuously (for 
eNpHR3.0). Stimulation lasted for 1 min and was preceded and followed by 30 seconds 
of recording without stimulation. 
For simultaneous electrophysiology and GCaMP6s imaging, current-clamped 
neurons were stimulated (0.5-1 nA) to elicit action potentials. Stimulation occurred at 10 
Hz; 50 or 60 Hz; 100 or 120 Hz (100 µs pulse-width); or was delivered as a long single 
square wave of constant current for 1 min, preceded and followed by 30 seconds 
without stimulation. During the duration of each 2 min trial GCaMP fluorescence was 
either acquired through 1-photon or 2-photon microscopy. 1-photon experiments used a 
473 nm light (TTL-controlled LED, Olympus, paired with GFP filter, Chroma) delivered 
to the slice at <1 mW, with GCaMP6s fluorescence captured using an imaging camera 
attached to the microscope (QI Retiga Electro). For 2-photon microscopy, a 2-photon 
source (Coherent Ultra II) was tuned to 810 nm to identify GCaMP expressing neurons, 
and tuned to 940 nm for calcium imaging. Epi- and transfluorescence signals were 
captured through a 40×, 0.8 NA objective paired with a 1.4 NA oil immersion condenser 
(Olympus) to photomultiplier tubes (H10770PA-40 PMTs, Hamamatsu). Data were 
collected in line scan mode (2–2.4 ms/line, including mirror flyback). 
All ex vivo electrical recordings were passed through a 1 Hz high-pass filter to 
remove slow electrical drift and spikes were extracted using the findpeaks function in 
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Matlab. All ex vivo optical recordings were first collapsed into a one-dimensional 
fluorescence time series by averaging the fluorescence of pixels within a defined region-
of-interest. In one-photon recordings, this signal was further processed by fitting a 
double exponential and subtracting it to remove effects of signal bleaching. 
Optogenetic Manipulations 
Prior to optical stimulation experiments, animals were habituated to tethering with custom 
lightweight patch cables (Precision Fiber Products and ThorLabs) coupled to an optical 
commutator (Doric Lenses) in the open field for 30 min per day, over 1-2 days. Optical 
stimulation sessions consisted of five 1 min stimulation periods, each preceded and 
followed by 1 min of no stimulation, for a total of 11 min. TTL-controlled (Master8, 
A.M.P.I.) blue (488 nm, 3 mW, Shanghai Laser and Optics Century) or green laser light 
(593 nm, 6 mW, Shanghai Laser and Optics Century) was delivered in pulse trains (3 ms, 
50Hz) or continuously, respectively. 
Histology and Microscopy 
Mice were terminally anesthetized with IP ketamine (200 mg/kg) and xylazine (40 mg/kg). 
For mice with an implanted STN DBS device, the site of stimulation was marked with a 
solid state, direct current Lesion Maker (Ugo Basile). Mice were then transcardially 
perfused with 4% paraformaldyde (PFA), the brain was dissected from the skull and fixed 
overnight in 4% PFA, and then was placed in 30% sucrose at 4°C for 2-3 days. Brains 
were then cut into 50 μm sagittal sections on a freezing microtome (Leica). To confirm 
dopamine depletion, tissue was immunostained for tyrosine hydroxylase (TH). Stitched 
multi-channel fluorescence images were taken on a Nikon 6D conventional widefield 
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microscope at 4-10X, using custom software (UCSF Nikon Imaging Center) to confirm 
virus expression, fiber placement, and STN DBS placement on a subset of animals. 
Quantification and Statistical Analysis 
All data are expressed as mean ± standard error of the mean (SEM). For all bar graphs 
for electrical stimulation, optogenetic, and slice experiments, the “stim” bar was calculated 
by averaging all one-minute stimulation periods for each trial. The “pre” and “post” bars 
were calculated by averaging the 30 seconds before and 30 seconds after each 
stimulation period, respectively. For all bar graphs involving levodopa or saline, the “LD” 
or “saline” bar was calculated by averaging the ten minutes between 30-40 min post 
injection for each trial. The “pre” and “post” bars were calculated by averaging the ten 
minutes 15-5 min before injection and 125-135 min post injection, respectively, for each 
trial. Rise time of velocity and calcium signals was calculated as the time it took from the 
onset of stimulation for the signal to first reach the mean value for that stimulation epoch. 
All data was tested for normality using a Kolmogorov-Smirnov (KS) test. A 
Friedman test was used for data that did not pass the KS test (Supplementary Fig 3.1D,H-
I,M-N), and a one-way repeated measures ANOVA was used for data that did (all other 
figures). In both cases, a Tukey HSD post hoc analysis was applied to correct for multiple 
comparisons. Data was considered statistically significant for p<0.05. 
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Figure 3.1 
 
 
Figure 3.1. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) 
increases STN activity. Hemiparkinsonian VGlut2-Cre mice were injected with Cre-
dependent GCaMP6s and implanted with an electrical DBS device and optical fiber in the 
ipsilateral STN.  (A) Experimental timeline. (B) Left: Sagittal schematic showing STN DBS 
and GCaMP fiber photometry. Right: Postmortem sagittal section showing GCaMP 
expression and estimated fiber placement in the STN (inset, scale=500 μm). (C) 
Representative single-session velocity (black) and STN GCaMP signal (blue) before and 
after levodopa injection (dotted line). (D) Average velocity (top) and STN GCaMP signal 
(bottom) before, during, and after levodopa treatment. (E) Representative single-session 
velocity (black) and STN GCaMP signal (blue) in response to 60 Hz STN DBS. (F) 
Average velocity (top) and STN GCaMP signal (bottom) before, during, and after 60 Hz 
STN DBS. (G) Representative single-session velocity (black) and STN GCaMP signal 
(blue) in response to 100 Hz STN DBS. (H) Average velocity (top) and STN GCaMP 
signal (bottom) before, during, and after 100 Hz STN DBS. Arrowhead in velocity traces 
and GCaMP traces corresponds to 1 cm/s and 0 z-score, respectively. N=9 mice. Bar 
plots show mean ± SEM. 
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Figure 3.2 
 
 
Figure 3.2. STN DBS and levodopa have opposite effects on activity in the 
substantia nigra pars reticulata (SNr). Hemiparkinsonian mice were injected with 
GCaMP6s in the SNr and implanted with an electrical DBS device in the STN and an 
optical fiber in the ipsilateral SNr. (A) Left: Sagittal schematic showing STN DBS and SNr 
GCaMP fiber photometry. Right: Postmortem sagittal section showing GCaMP 
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expression and estimated fiber placement in the SNr (inset, scale=500 μm). (B) 
Representative single-session velocity (black) and SNr GCaMP signal (purple) before and 
after levodopa injection (dotted line). (C) Average velocity (top) and SNr GCaMP signal 
(bottom) before, during, and after levodopa treatment. (D) Representative single-session 
velocity (black) and SNr GCaMP signal (purple) in response to 60 Hz STN DBS. (E) 
Average velocity (top) and SNr GCaMP signal (bottom) before, during, and after 60 Hz 
STN DBS (N=7 mice). (F) Representative single-session velocity (black) and SNr GCaMP 
signal (purple) in response to 100 Hz STN DBS. (G) Average velocity (top) and SNr 
GCaMP signal (bottom) before, during, and after 100 Hz STN DBS (N=7 mice). 
Arrowhead in velocity traces and GCaMP traces corresponds to 1 cm/s and 0 z-score, 
respectively. N=7-8 mice. Bar plots show mean ± SEM. 
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Figure 3.3 
 
 
 85 
Figure 3.3. The responses of hyperdirect primary motor cortex (M1) neurons to STN 
DBS do not consistently correlate with motor benefits. To target hyperdirect pathway 
(STN-projecting M1) neurons, hemiparkinsonian mice were injected with a retrograde 
virus encoding Cre in the STN, and Cre-dependent GCaMP6s in the ipsilateral M1 cortex. 
(A) Left: Sagittal schematic showing STN DBS and M1-STN GCaMP fiber photometry. 
Right: Postmortem sagittal section showing GCaMP expression in M1 (inset, scale=500 
μm). (B) Representative single-session velocity (black) and M1-STN GCaMP signal 
(green) before and after levodopa injection (dotted line). (C) Average velocity (top) and 
M1-STN GCaMP signal (bottom) before, during, and after levodopa treatment. (D) 
Representative single-session velocity (black) and M1-STN GCaMP signal (green) in 
response to 60 Hz STN DBS. Vertical arrows indicate a decrease in GCaMP signal 
following stimulation onset. (E) Average velocity (top) and M1-STN GCaMP signal 
(bottom) before, during, and after 60 Hz STN DB. (F) Representative single-session 
velocity (black) and M1-STN GCaMP signal (green) in response to 100 Hz STN DBS. (G) 
Average velocity (top) and M1-STN GCaMP signal (bottom) before, during, and after 100 
Hz STN DB. (H) Proportion of mice in which the indicated brain regions showed an 
increase or decrease in GCaMP signal during levodopa treatment (left), 60 Hz STN DBS 
(center), or 100 Hz STN DBS (right). Arrowhead in velocity traces and GCaMP traces 
corresponds to 1 cm/s and 0 z-score, respectively. N=8-9 mice. Bar plots show mean ± 
SEM. 
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Figure 3.4 
 
 
 
Figure 3.4. Optogenetic inhibition of SNr and optogenetic excitation of STN 
increase movement in parkinsonian mice. (A-G) Hemiparkinsonian VGAT-Cre mice 
were injected with Cre-dependent eNphR3.0 or eYFP, and implanted with an optical fiber 
in the ipsilateral SNr. (A) Left: Sagittal schematic showing viral injection and optical fiber 
implantation in the SNr. Right: Postmortem sagittal section showing eYFP expression in 
the SNr (inset, scale=500μm). (B-D) Ex vivo recordings of SNr neurons in the cell-
attached configuration. (B) Recording configuration. (C) Representative SNr neuron 
before, during, and after green light stimulation (1 minute). 1 second portions of the sweep 
are shown below. (D) Average firing rate before, during, and after stimulation (n=17 cells, 
N=3 mice). (E) Representative single-session velocity in response to green light 
stimulation (1 minute). (F) Average velocity before, during, and after  stimulation (N=10 
mice). (G) Average rotation bias of parkinsonian mice before, during, and after stimulation 
(N=10 mice). (H-N) Hemiparkinsonian VGlut2-Cre mice were injected with Cre-dependent 
ChR2 or eYFP, and implanted with an optical fiber over the ipsilateral STN. (H) Left: 
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Sagittal schematic showing viral injection and optical fiber implantation in the STN. Right: 
Postmortem sagittal section showing ChR2 expression (inset, scale=500 μm). (I-K) Ex 
vivo recordings of STN neurons in the cell-attached configuration. (I) Recording 
configuration. (J) Representative STN neuron before, during, and after pulsatile blue light 
stimulation (1 min, 50Hz). 1 second portions of the sweep are shown below. (K) Average 
firing rate before, during, and after blue light stimulation (n=13 cells, N=3 mice). (L) 
Representative single-session velocity in response to 50 Hz blue light stimulation. (M) 
Average velocity before, during, and after 50 Hz blue light stimulation (N=8 mice). (N) 
Average rotation bias of parkinsonian mice before, during, and after stimulation (N=8 
mice). Arrowhead in cell-attached recordings and velocity traces corresponds to 0 pA and 
1 cm/s, respectively. Bar plots show mean ± SEM. 
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Supplemental Figure 3.1 
 
 
Supplemental Figure 3.1. Related to Figure 3.1. Levodopa and STN DBS produce 
similar behaviors in parkinsonian mice. Hemiparkinsonian mice were treated with 
levodopa (A-E) or STN DBS (F-N). (A) Representative single-session velocities before 
and after levodopa injection (dotted line) in 3 mice. (B) Average velocity over time, (C) 
Binned average velocity (left-middle), (D) rotational bias, and (E) dyskinesia in response 
to levodopa injection (N=32 mice). (F) Representative single-session velocities in 
response to 60 Hz STN DBS in 3 mice. (G) Average velocity over time, (H) binned 
average velocity, (I) rotational bias, and (J) dyskinesia  in response to 60 Hz STN DBS 
(N=39 mice). (K) Representative single-session velocities in response to 100 Hz STN 
DBS in 3 mice. (L) Average velocity over time, (M) binned average velocity, (N) rotational 
bias, and (O) dyskinesia in response to 100 Hz STN DBS (N=36 mice). Arrowhead in 
velocity traces corresponds to 1 cm/s. Bar plots show mean ± SEM. 
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Supplemental Figure 3.2 
 
 
Supplemental Figure 3.2. Related to Figure 3.1. STN stimulation increases STN 
activity in vitro and in vivo. VGlut2-Cre mice were injected with Cre-dependent 
GCAMP6s in the STN. (A-C) Average velocity over time (black) and STN GCaMP signal 
(blue) following administration of levodopa (H, N=9 mice), 60 Hz STN DBS (I, N=9 mice), 
or 100 Hz STN DBS (J, N=9 mice). (D) Average rotation bias before, during, and after 
levodopa (top, N=9 mice), 60 Hz STN DBS (middle, N=9 mice), or 100 Hz STN DBS 
(bottom, N=9 mice). (E) Average velocity (top), STN GCaMP signal (middle), and 
rotational bias before, during, and after saline injection (N=9 mice). (F-L) Combined 
electrophysiological and calcium imaging recordings in STN neurons from ex vivo slices. 
Neurons were patched in the whole-cell current-clamp configuration. (F) Recording 
configuration. (G) Schematic showing current-clamp stimulation protocol. (H) 
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Representative STN neuron responses to the indicated current-clamp stimulation. (I) 
Average firing rate of STN neurons in response to stimulation (n=5 cells, N=2 mice). (J) 
Image of GCaMP-expressing STN neuron. (K) Representative trace of Z-scored STN 
GCaMP signal in response to current-clamp stimulation. (L) Average Z-scored STN 
GCaMP signal in response to current-clamp stimulation (n=5 cells, N=2 mice). Arrowhead 
in voltage-clamp traces, velocity traces, and GCaMP traces corresponds to -75 mV, 1 
cm/s, and 0 z-score, respectively. Bar plots show mean ± SEM. 
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Supplemental Figure 3.3 
 
 
Supplemental Figure 3.3. Related to Figure 3.2. STN DBS evokes a rapid increase 
in SNr activity. Hemiparkinsonian mice were injected with GCaMP6s in the SNr and 
implanted with an electrical DBS device in the STN and an optical fiber in the ipsilateral 
SNr. (A-C) Average velocity over time (black) and SNr GCaMP signal (purple) following 
administration of levodopa (A, N=8 mice), 60 Hz STN DBS (B, N=7 mice), or 100 Hz STN 
DBS (C, N=7 mice). (D) Average rotation bias before, during, and after levodopa 
administration (top, N=8 mice), 60 Hz STN DBS (middle, N=7 mice), or 100 Hz STN DBS 
(bottom, N=7 mice). (E) Average velocity (top), SNr GCaMP signal (middle), and 
rotational bias before, during, and after saline injection (N=8 mice). Arrowhead in velocity 
traces and GCaMP traces corresponds to 1 cm/s and 0 z-score, respectively. Bar plots 
show mean ± SEM. 
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Supplemental Figure 3.4 
 
 
Supplemental Figure 3.4. Related to Figure 3.3. STN DBS drives inconsistent and 
slow changes to hyperdirect M1 activity. To target hyperdirect pathway (STN-
projecting M1) neurons, hemiparkinsonian mice were injected with a retrograde virus 
encoding Cre in the STN, and Cre-dependent GCaMP6s in the ipsilateral M1 cortex. (A-
C) Average velocity over time (black) and M1-STN GCaMP signal (green) following 
administration of levodopa (A, N=8 mice), 60 Hz STN DBS (B, N=9 mice), or 100 Hz STN 
DBS (C, N=8 mice). (D) Average rotation bias before, during, and after levodopa 
administration (top, N=8 mice), 60 Hz STN DBS (middle, N=9 mice), or 100 Hz STN DBS 
(bottom, N=8 mice). (E) Average velocity (top), M1-STN GCaMP signal (middle), and 
rotational bias before, during, and after saline injection (N=8 mice). Arrowhead in velocity 
traces and GCaMP traces corresponds to 1 cm/s and 0 z-score, respectively. Bar plots 
show mean ± SEM. 
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Supplemental Figure 3.5 
 
 
Supplemental Figure 3.5. Related to Figure 3.4. The time course of optically evoked 
changes in ex vivo firing rate parallel those in in vivo movement velocity. (A,B,E) 
Hemiparkinsonian VGAT-Cre mice were injected with eNpHR3.0 or eYFP in the 
ipsilesional SNr and implanted with an optical fiber over the SNr. (A) SNr neurons were 
patched in the cell-attached configuration in ex vivo brain slices. Average firing rate in 
response to continuous green light (n=17 cells, N=3 mice). (B) Average movement 
velocity in response to green light (N=10 mice). (C,D,F) Hemiparkinsonian VGlut2-Cre 
mice were injected with ChR2 or eYFP in the ipsilesional STN and implanted with an 
optical fiber over the STN. (C) STN neurons were patched in the cell attached 
configuration in ex vivo brain slices. Average firing rate in response to pulsatile (50 Hz) 
blue light stimulation (n=13 cells, N=3 mice). (D) Average movement velocity in response 
to pulsatile (50 Hz) blue light stimulation (N=8 mice). (E) Average movement velocity 
before, during, and after green light stimulation in mice injected with eYFP (N=7 mice). 
(F) Average movement velocity before, during, and after blue light stimulation in mice 
injected with eYFP (N=9 mice). Arrowhead in rate histograms and velocity traces 
corresponds to 5 Hz and 1 cm/s, respectively. Bar plots show mean ± SEM. 
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Conclusions 
The work detailed here is a crucial step in understanding not only how DBS acts 
to alleviate symptoms of Parkinson’s Disease, but also in providing a model for assessing 
the efficacy and mechanism of DBS in other neuropsychiatric disorders. In Chapter 1, we 
introduced STN DBS as a therapy for PD, and noted critical gaps in our current 
understanding of its mechanism. In Chapter 2, we established and characterized the first 
parkinsonian mouse model of electrical STN DBS. We used the model to characterize the 
relationship between stimulation parameters and therapeutic efficacy. We developed a 
simple composite metric for the stimulation parameters, which in turn predicted the 
therapeutic benefit in parkinsonian mice, in terms of movement velocity. Excitingly, this 
relationship was (1) linear, and (2) held even when applied retrospectively to human data. 
In Chapter 3, we utilized our mouse model to observe how STN DBS and levodopa alter 
activity in the STN and two connected regions within basal ganglia circuits, and then 
demonstrated that the opposing effects of these two therapies are both, paradoxically, 
therapeutic. 
However, as with most scientific inquiries, we are still left with a number of 
questions. First and foremost, we do not fully understand the intriguing observation that 
bidirectional changes in basal ganglia activity relieve parkinsonian bradykinesia. This is 
in direct contradiction with the predictions of the classical rate-based model of basal 
ganglia activity1,2, which posits that decreases in basal ganglia activity should be 
prokinetic, while increases in basal ganglia activity should inhibit movement (worsening 
parkinsonism). As noted in the Introduction and Chapter 3, though, an increasing body of 
literature suggests that the rate model may not fully capture the relationship between 
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basal ganglia activity and movement3,4. Instead, a parallel body of literature suggests that 
patterning and neural synchrony may drive bradykinesia in PD. Within this literature, there 
are further debates between those who believe LFP oscillations at a specific frequency 
reflect the causal circuit mechanisms of PD, and those who suspect other elements of 
pattern, such as rhythmic bursting, may drive parkinsonism5–9. Disruption of either of 
these electrophysiological abnormalities (oscillations or rhythmic bursting) might then 
relieve the motor symptoms of PD. In fact, it may be that both increases or decreases in 
overall firing rates disrupt pathological oscillations, or that both increases and decreases 
in firing rates can regularize firing patterns. Though we suspect that our results may 
support some of these theories, we will discuss shortly the technical limitations that to 
date prevent us from fully addressing this question. 
In considering how DBS might relieve parkinsonian motor deficits, another area for 
future study lies outside of the basal ganglia. While we addressed how STN DBS changes 
the activity of both a key STN input (hyperdirect pathway M1 neurons) and its canonical 
output (the SNr), the STN projects out of the basal ganglia to a number of motor-related 
structures, particularly the mesenphalic locomotor region (MLR). As its name suggests, 
the MLR has been implicated in locomotor control10–12. Even more strikingly, a subregion 
of the MLR, the pedunculopontine nucleus (PPN) shows changes in connectivity and 
activity in parkinsonian rats13 and direct stimulation of the PPN may help to alleviate 
parkinsonian symptoms in humans14, although results have been mixed15. It will be 
important for future studies to explore the possible involvement of areas such as the MLR 
in mediating the therapeutic effects of STN DBS. 
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When I began investigating STN DBS, I had the rather lofty goal of unraveling the 
mechanism of DBS during the course of my PhD. Though I believe we have made crucial 
progress towards this goal, there is without a doubt more work to be done. How, then, 
might we conceive of a path forward? Though we were able to avoid the electrical artifacts 
that have hindered electrophysiological recordings during DBS in the past, our recording 
method did not achieve single-cell resolution, nor did it use a signal that varied on the 
time scale of voltage. I believe that in order to determine how STN DBS exerts its 
therapeutic benefit, we will need to overcome both of these limitations so that we can 
assess how STN DBS affects synchrony and patterning among individual neurons.  
Achieving single-cell resolution is perhaps the easier of the two. Rather than using 
bulk fiber photometry calcium imaging, we have begun to image GCaMP in individual 
cells during STN DBS using a GRIN lens and a CMOS chip16. This has provided us with 
our first look into how individual neurons respond to stimulation, and has the potential to 
reveal changes bursting, or in the synchronization of calcium signals across a population 
of neurons. However, the current generation of calcium sensors are far too slow to reflect 
individual action potentials, especially in areas like the STN or SNr, where neurons fire 
tonically at very high rates17. Ideally, one would use genetically encoded voltage 
indicators18 (GEVIs) rather than calcium indicators, given that they can be imaged at 
much higher rates and, perhaps even more importantly, their output directly corresponds 
to neuronal spiking. So far, while GEVIs have been used to perform bulk-voltage 
imaging19 in freely behaving animals, or to perform head-fixed recordings of individual 
neurons in small groups20, the combination of freely moving, single-cell, high spatial 
resolution, and fast acquisition rate have yet to be attained, particularly in deep structures. 
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In large part this is a technical problem; commercial CMOS chips were never intended for 
the speeds and resolutions ideal for large-scale GRIN lens voltage imaging. It is likely, 
given the pace of technology, that we will eventually have the ability to perform these 
types of recordings, but until then it will be challenging to apply our optical methods to 
more satisfyingly identify the mechanisms underlying STN DBS. 
Despite these limitations, the knowledge obtained here can still be utilized, along 
with other models and physiological techniques, to inform improvements in STN DBS in 
PD. In addition, our approach may be useful as other investigators explore other 
neuropsychiatric diseases for which STN DBS might prove therapeutic. Having now 
established a model of electrical STN DBS, we are excited to assess the efficacy of basal 
ganglia DBS in other movement disorders, including those which have not yet been 
treated with DBS. As greater knowledge of the circuit mechanisms of other 
neuropsychiatric diseases is developed, mouse models of DBS may also help provide a 
rational framework for the identification of new DBS targets or modes of stimulation. Given 
the wide array of disease models available in mice and the relative ease of high 
throughput studies, we see this as the ideal tool for screening and assessing the efficacy 
of STN DBS before testing in human patients. 
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